Prognostic value of tumor oxygenation in 397 head and radiation therapy. An international multi-center study

Radiotherapy and Oncology 77, 18-24

DOI: 10.1016/j.radonc.2005.06.038

Citation Report

#	Article	IF	CITATIONS
1	A physical standard of the unit of electrical resistance based on the quantum Hall effect. Uspekhi Fizicheskikh Nauk, 1988, 31, 880-881.	0.3	8
2	Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncology, The, 2005, 6, 757-764.	5.1	264
3	Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiotherapy and Oncology, 2006, 78, 138-145.	0.3	17
4	The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiotherapy and Oncology, 2006, 79, 288-297.	0.3	91
5	Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer. Radiotherapy and Oncology, 2006, 80, 51-56.	0.3	7
6	The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 2006, 80, 123-131.	0.3	98
7	Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models. Radiotherapy and Oncology, 2006, 80, 165-171.	0.3	13
8	Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiotherapy and Oncology, 2006, 80, 112-122.	0.3	78
9	Imaging hypoxia after oxygenation-modification: Comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiotherapy and Oncology, 2006, 80, 157-164.	0.3	72
10	Bridging gaps in translational radiation oncology. Radiotherapy and Oncology, 2006, 80, 109-111.	0.3	4
11	Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. Radiotherapy and Oncology, 2006, 81, 122-129.	0.3	102
12	Preclinical safety and antitumor efficacy of insulin combined with irradiation. Radiotherapy and Oncology, 2006, 81, 112-117.	0.3	15
13	Tumour hypoxia $\hat{a} \in A$ characteristic feature with a complex molecular background. Radiotherapy and Oncology, 2006, 81, 119-121.	0.3	17
14	Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): The technical basis, ICRU-target volumes, problems, perspectives. Radiotherapy and Oncology, 2006, 81, 209-225.	0.3	207
15	Knockdown of hypoxia-inducible factor- \hat{l} in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochemical and Biophysical Research Communications, 2006, 342, 1341-1351.	1.0	61
16	Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resistance Updates, 2006, 9, 185-197.	6.5	37
17	Radiotherapy for head and neck cancer: latest developments and future perspectives. Current Opinion in Oncology, 2006, 18, 240-246.	1.1	15
18	Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor- $11\pm$ -related markers, and hemoglobin levels. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1481-1487.	0.4	55

#	Article	IF	CITATIONS
19	Does the tumor microenvironment influence radiation-induced apoptosis?. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1727-1735.	2.2	31
20	FDGâ€"a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1426-1431.	3.3	116
21	High-Precision Radiation Therapy with Integrated Biological Imaging and Tumor Monitoring. Strahlentherapie Und Onkologie, 2006, 182, 361-368.	1.0	29
22	Endogenous Hypoxia Markers in Locally Advanced Cancers of the Uterine Cervix: Reality or Wishful Thinking?. Strahlentherapie Und Onkologie, 2006, 182, 501-510.	1.0	37
23	Impact of Hemoglobin Levels on Tumor Oxygenation: the Higher, the Better?. Strahlentherapie Und Onkologie, 2006, 182, 63-71.	1.0	120
24	Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer, 2006, 6, 207.	1.1	56
25	Split Course Hyperfractionated Accelerated Radio-Chemotherapy (SCHARC) for patients with advanced head and neck cancer: Influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. BMC Cancer, 2006, 6, 279.	1.1	7
26	The chemokine receptor CXCR4: A homing device for hypoxic cancer cells?. Cancer Biology and Therapy, 2006, 5, 1563-1565.	1.5	6
27	Hypoxia in head and neck cancer. British Journal of Radiology, 2006, 79, 791-798.	1.0	76
28	The emerging evidence for Stereotactic Body Radiotherapy. Acta Oncológica, 2006, 45, 771-774.	0.8	20
29	ER Stress, Hypoxia Tolerance and Tumor Progression. Current Molecular Medicine, 2006, 6, 55-69.	0.6	210
30	Hypoxia-Inducible Factor-1α and Hypoxia-Inducible Factor-2α Are Expressed in Kaposi Sarcoma and Modulated by Insulin-like Growth Factor-I. Clinical Cancer Research, 2006, 12, 4506-4514.	3.2	58
31	Acidic Extracellular pH Promotes Experimental Metastasis of Human Melanoma Cells in Athymic Nude Mice. Cancer Research, 2006, 66, 6699-6707.	0.4	581
32	Development of radiobiology for oncologyâ€"a personal view. Physics in Medicine and Biology, 2006, 51, R263-R286.	1.6	56
33	Hypoxic Stress Induces Dimethylated Histone H3 Lysine 9 through Histone Methyltransferase G9a in Mammalian Cells. Cancer Research, 2006, 66, 9009-9016.	0.4	200
34	The role of hypoxia inducible factor-1 in cell metabolism – a possible target in cancer therapy. Expert Opinion on Therapeutic Targets, 2006, 10, 583-599.	1.5	14
35	Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum. Journal of Clinical Oncology, 2006, 24, 2612-2617.	0.8	87
36	Biological Basis of Combined Radio- and Chemotherapy. , 2006, , 3-17.		4

#	ARTICLE	IF	CITATIONS
37	The PERK/eIF2 $\hat{1}$ ±/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biology and Therapy, 2006, 5, 723-728.	1.5	307
38	Chemoradiotherapy for Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2007, 25, 4118-4126.	0.8	79
39	Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis. Clinical Cancer Research, 2007, 13, 1971-1978.	3.2	154
40	Phase II Trial of Chemoradiation for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. Journal of Clinical Oncology, 2007, 25, 3971-3977.	0.8	136
41	Glucocorticoids Modulate Tumor Radiation Response through a Decrease in Tumor Oxygen Consumption. Clinical Cancer Research, 2007, 13, 630-635.	3.2	48
42	Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG. Current Medical Imaging, 2007, 3, 178-185.	0.4	8
43	Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers. Cancer Research, 2007, 67, 3441-3449.	0.4	349
44	Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Physics in Medicine and Biology, 2007, 52, 499-513.	1.6	77
45	Detection and Characterization of Tumor Hypoxia Using pO2 Histography. Antioxidants and Redox Signaling, 2007, 9, 1221-1236.	2.5	628
46	Radiation Therapy Plus Angiogenesis Inhibition with Bevacizumab: Rationale and Initial Experience. Reviews on Recent Clinical Trials, 2007, 2, 163-168.	0.4	23
47	Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx, 2007, 34, 343-346.	0.5	16
48	Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiotherapy and Oncology, 2007, 82, 10-17.	0.3	46
49	Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2007, 85, 156-170.	0.3	152
50	Tissue characterization of locoregionally advanced head-and-neck squamous cell carcinoma (HNSCC) using quantified ultrasonography: A prospective phase II study on prognostic relevance. Radiotherapy and Oncology, 2007, 85, 48-57.	0.3	3
51	Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiotherapy and Oncology, 2007, 83, 367-373.	0.3	157
52	Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiotherapy and Oncology, 2007, 83, 389-397.	0.3	80
53	Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. Radiotherapy and Oncology, 2007, 83, 346-352.	0.3	24
54	Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiotherapy and Oncology, 2007, 83, 340-345.	0.3	21

#	Article	IF	CITATIONS
55	Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. Radiotherapy and Oncology, 2007, 83, 362-366.	0.3	63
56	Phosphorylation of eIF2α is required for mRNA translation inhibition and survival during moderate hypoxia. Radiotherapy and Oncology, 2007, 83, 353-361.	0.3	54
57	Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study. Radiotherapy and Oncology, 2007, 83, 383-388.	0.3	56
58	Tumor Hypoxia in Cancer Therapy. Methods in Enzymology, 2007, 435, 295-321.	0.4	254
59	Hypoxic Radiosensitization: Adored and Ignored. Journal of Clinical Oncology, 2007, 25, 4066-4074.	0.8	564
60	Dynamics of Tumor Hypoxia Measured with Bioreductive Hypoxic Cell Markers. Radiation Research, 2007, 167, 127-145.	0.7	153
61	Hypoxia and prognosis: the oxygen tension mounts. Frontiers in Bioscience - Landmark, 2007, 12, 3502.	3.0	8
62	3â€fâ€fRadiotherapy predictive assays. , 2007, , 35-50.		1
63	Tumor microenvironment in head and neck squamous cell carcinomas: Predictive value and clinical relevance of hypoxic markers. A review. Head and Neck, 2007, 29, 591-604.	0.9	107
64	Cell Kinetics. Clinical Oncology, 2007, 19, 370-384.	0.6	22
65	The Hypoxic Tumour Microenvironment, Patient Selection and Hypoxia-modifying Treatments. Clinical Oncology, 2007, 19, 385-396.	0.6	68
66	Hyperthermia: a Potent Enhancer of Radiotherapy. Clinical Oncology, 2007, 19, 418-426.	0.6	389
67	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2007, 69, 167-175.	0.4	111
68	Radiotherapy Adapted to Spatial and Temporal Variability in Tumor Hypoxia. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1496-1504.	0.4	70
69	Identifying and Targeting Hypoxia in Head and Neck Cancer: A Brief Overview of Current Approaches. International Journal of Radiation Oncology Biology Physics, 2007, 69, S56-S58.	0.4	19
70	Hypoxia in Head and Neck Cancer: Studies With Hypoxic Positron Emission Tomography Imaging and Hypoxic Cytotoxins. International Journal of Radiation Oncology Biology Physics, 2007, 69, S61-S63.	0.4	32
71	Hypoxia Imaging With FAZA-PET and Theoretical Considerations With Regard to Dose Painting for Individualization of Radiotherapy in Patients With Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 541-551.	0.4	226
72	Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clinical Otolaryngology, 2007, 32, 337-345.	0.6	52

#	ARTICLE	IF	Citations
73	pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?. BMC Cancer, 2007, 7, 113.	1.1	67
74	Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer, 2007, 7, 213.	1.1	76
75	Oxygen sensing and the DNA-damage response. Current Opinion in Cell Biology, 2007, 19, 680-684.	2.6	46
76	Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nature Clinical Practice Oncology, 2007, 4, 172-180.	4.3	129
77	Imaging oxygenation of human tumours. European Radiology, 2007, 17, 861-872.	2.3	304
78	Technical Improvement of pO2 Measurements in Breast Cancer. Strahlentherapie Und Onkologie, 2007, 183, 265-270.	1.0	4
79	Modulation of Glucose Metabolism Inhibits Hypoxic Accumulation of Hypoxia-Inducible Factor- $1\hat{l}\pm$ (HIF- $1\hat{l}\pm$). Strahlentherapie Und Onkologie, 2007, 183, 366-373.	1.0	31
80	PET/CT in head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1329-1333.	3.3	12
81	Hypoxia in cancer: significance and impact on clinical outcome. Cancer and Metastasis Reviews, 2007, 26, 225-239.	2.7	1,918
82	Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer and Metastasis Reviews, 2007, 26, 241-248.	2.7	364
83	Clinical biomarkers for hypoxia targeting. Cancer and Metastasis Reviews, 2008, 27, 351-362.	2.7	70
84	Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1803-1811.	3.3	85
85	Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2294-2303.	3.3	104
86	Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemotherapy and Pharmacology, 2008, 61, 377-393.	1.1	74
87	Immunohistochemical Detection of HIF-1 \hat{l} ± and CAIX in Advanced Head-and-Neck Cancer. Strahlentherapie Und Onkologie, 2008, 184, 393-399.	1.0	38
88	Dynamic monitoring of localized tumor oxygenation changes using RF pulsed electron paramagnetic resonance in conscious mice. Magnetic Resonance in Medicine, 2008, 59, 619-625.	1.9	18
89	Design, synthesis, and radiosensitizing activities of sugar-hybrid hypoxic cell radiosensitizers. Bioorganic and Medicinal Chemistry, 2008, 16, 675-682.	1.4	29
90	Prognostic Significance of Tumor Hypoxia Inducible Factor–1α Expression for Outcome After Radiotherapy in Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1551-1559.	0.4	49

#	Article	IF	CITATIONS
91	Fluorine-18-Labeled Fluoromisonidazole Positron Emission and Computed Tomography-Guided Intensity-Modulated Radiotherapy for Head and Neck Cancer: A Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2008, 70, 2-13.	0.4	220
92	Reproducibility of Intratumor Distribution of 18F-Fluoromisonidazole in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 70, 235-242.	0.4	209
93	In Vivo 1H Magnetic Resonance Spectroscopy of Lactate in Patients With Stage IV Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1151-1157.	0.4	26
94	Imaging Hypoxia in Xenografted and Murine Tumors With 18F-Fluoroazomycin Arabinoside: A Comparative Study Involving microPET, Autoradiography, Po2-Polarography, and Fluorescence Microscopy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1202-1212.	0.4	79
95	Overexpression of Intrinsic Hypoxia Markers HIF1 $\hat{I}\pm$ and CA-IX Predict for Local Recurrence in Stage T1-T2 Glottic Laryngeal Carcinoma Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 72, 161-169.	0.4	94
96	Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer, 2008, 8, 545-554.	12.8	766
97	Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Ecological Management and Restoration, 2008, 21, 195-200.	0.2	21
98	From Cellular to High-Throughput Predictive Assays in Radiation Oncology: Challenges and Opportunities. Seminars in Radiation Oncology, 2008, 18, 75-88.	1.0	45
99	Targeted Molecular Imaging in Oncology: Focus on Radiation Therapy. Seminars in Radiation Oncology, 2008, 18, 136-148.	1.0	27
100	Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. Oral Oncology, 2008, 44, 335-344.	0.8	17
101	Molecular aspects of tumour hypoxia. Molecular Oncology, 2008, 2, 41-53.	2.1	126
102	New Developments in Radiation Therapy for Head and Neck Cancer: Intensity-Modulated Radiation Therapy and Hypoxia Targeting. Seminars in Oncology, 2008, 35, 236-250.	0.8	39
103	Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nuclear Medicine and Biology, 2008, 35, 273-279.	0.3	51
105	The role of hypoxia in canine cancer. Veterinary and Comparative Oncology, 2008, 6, 213-223.	0.8	9
106	An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response. Physics in Medicine and Biology, 2008, 53, 4471-4488.	1.6	64
107	Fundamentals of Molecular Imaging: Rationale and Applications With Relevance for Radiation Oncology. Seminars in Nuclear Medicine, 2008, 38, 119-128.	2.5	25
108	Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy. Radiotherapy and Oncology, 2008, 86, 354-360.	0.3	24
109	Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncology, The, 2008, 9, 288-296.	5.1	306

#	Article	IF	CITATIONS
110	The Pervasive Presence of Fluctuating Oxygenation in Tumors. Cancer Research, 2008, 68, 5812-5819.	0.4	163
111	Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells. Cancer Research, 2008, 68, 257-265.	0.4	60
112	Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance. Cancer Research, 2008, 68, 605-614.	0.4	286
113	Comparison of Helzel and OxyLite Systems in the Measurements of Tumor Partial Oxygen Pressure (<i>p</i> O ₂). Radiation Research, 2008, 169, 67-75.	0.7	25
114	Resolution in PET hypoxia imaging: Voxel size matters. Acta Oncológica, 2008, 47, 1201-1210.	0.8	62
115	Assessing Tumor Hypoxia in Cervical Cancer by PET with ⁶⁰ Cu-Labeled Diacetyl-Bis(<i>N</i> ⁴ -Methylthiosemicarbazone). Journal of Nuclear Medicine, 2008, 49, 201-205.	2.8	221
116	Plasma Osteopontin, Hypoxia, and Response to Radiotherapy in Nasopharyngeal Cancer. Clinical Cancer Research, 2008, 14, 7080-7087.	3.2	35
117	Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Physics in Medicine and Biology, 2008, 53, 4153-4167.	1.6	69
118	Efficient Monte Carlo modelling of individual tumour cell propagation for hypoxic head and neck cancer. Physics in Medicine and Biology, 2008, 53, 4489-4507.	1.6	18
119	Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncology, 2008, 4, 689-704.	1.1	13
120	Imaging of Tumor Hypoxia to Predict Treatment Sensitivity. Current Pharmaceutical Design, 2008, 14, 2932-2942.	0.9	34
121	Clinical Role of F-18 FDG PET/CT in Squamous Cell Carcinoma of Head and Neck. Hanyang Medical Reviews, 2009, 29, 274.	0.4	0
123	Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer. Journal of Oncology, 2009, 2009, 1-13.	0.6	118
124	Recent Advances in Image-Guided Radiotherapy for Head and Neck Carcinoma. Journal of Oncology, 2009, 2009, 1-10.	0.6	17
126	Dose Painting in Radiotherapy for Head and Neck Squamous Cell Carcinoma: Value of Repeated Functional Imaging with sup > 18 < sup > F-FDG PET, sup > 18 < sup > F-Fluoromisonidazole PET, Diffusion-Weighted MRI, and Dynamic Contrast-Enhanced MRI. Journal of Nuclear Medicine, 2009, 50, 1020-1027.	2.8	200
127	Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Physics in Medicine and Biology, 2009, 54, 2179-2196.	1.6	55
128	Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine <i>N</i> 3 DNA minor groove alkylators. Molecular Cancer Therapeutics, 2009, 8, 2903-2913.	1.9	36
129	Physical and Biological Basis of Proton and of Carbon Ion Radiation Therapy and Clinical Outcome Data. Reviews of Accelerator Science and Technology, 2009, 02, 1-15.	0.5	5

#	Article	IF	CITATIONS
130	Quantitative optical spectroscopy can identify long-term local tumor control in irradiated murine head and neck xenografts. Journal of Biomedical Optics, 2009, 14, 054051.	1.4	53
131	Biological imaging in radiation therapy: role of positron emission tomography. Physics in Medicine and Biology, 2009, 54, R1-R25.	1.6	138
132	DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity. Cancer Research, 2009, 69, 3884-3891.	0.4	76
134	Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck. International Journal of Radiation Biology, 2009, 85, 900-908.	1.0	9
135	Comparison of predicted and clinical response to radiotherapy: A radiobiology modelling study. Acta $Oncol\tilde{A}^3$ gica, 2009, 48, 584-590.	0.8	10
136	Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222. Journal of Clinical Oncology, 2009, 27, 3014-3019.	0.8	59
137	Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Molecular Cancer Therapeutics, 2009, 8, 1714-1723.	1.9	60
138	Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral Oncology, 2009, 45, 915-919.	0.8	30
139	Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer. International Journal of Colorectal Disease, 2009, 24, 1451-1458.	1.0	31
141	Molecular imaging of hypoxia with radiolabelled agents. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1674-1686.	3.3	190
142	Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 101-108.	0.4	126
143	Strategies for Biologic Image-Guided Dose Escalation: A Review. International Journal of Radiation Oncology Biology Physics, 2009, 73, 650-658.	0.4	90
144	Preliminary Study of Oxygen-Enhanced Longitudinal Relaxation in MRI: A Potential Novel Biomarker of Oxygenation Changes in Solid Tumors. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1209-1215.	0.4	107
145	The Relationship Between Human Papillomavirus Status and Other Molecular Prognostic Markers in Head and Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2009, 74, 553-561.	0.4	195
146	Decrease in Hemoglobin Levels Following Surgery Influences the Outcome in Head and Neck Cancer Patients Treated with Accelerated Postoperative Radiotherapy. Annals of Surgical Oncology, 2009, 16, 1331-1336.	0.7	7
147	Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck. International Journal of Radiation Biology, 2009, 85, 900-908.	1.0	14
148	Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: A pilot study in men with prostate cancer. International Journal of Radiation Biology, 2009, 85, 805-813.	1.0	101
149	On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Physics in Medicine and Biology, 2009, 54, 1483-1501.	1.6	57

#	Article	IF	CITATIONS
150	PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2009, 50, 74S-88S.	2.8	172
151	Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics. Radiotherapy and Oncology, 2009, 92, 443-449.	0.3	35
152	Chemoradiotherapy of head and neck cancer – Can the bumble bee fly?. Radiotherapy and Oncology, 2009, 92, 1-3.	0.3	15
153	Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiotherapy and Oncology, 2009, 92, 411-416.	0.3	130
154	Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3. Radiotherapy and Oncology, 2009, 92, 450-459.	0.3	86
155	Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?. Radiotherapy and Oncology, 2009, 92, 429-436.	0.3	50
156	Targeting the future in head and neck cancer. Lancet Oncology, The, 2009, 10, 204-205.	5.1	8
157	The Immunocompromised Host: Abdomen and Pelvis. , 2009, , 1365-1375.		0
158	Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy. Journal of Thoracic Oncology, 2009, 4, 463-471.	0.5	29
159	Tumor Hypoxia as a Modifier of DNA Strand Break and Cross-Link Repair. Current Molecular Medicine, 2009, 9, 401-410.	0.6	34
160	Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise. Current Molecular Medicine, 2009, 9, 442-458.	0.6	435
161	Monitoring of hemodynamic changes induced in the healthy breast through inspired gas stimuli with MR-guided diffuse optical imaging. Medical Physics, 2010, 37, 1638-1646.	1.6	18
162	Noninvasive Assessment of Tumor Microenvironment Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging and 18F-Fluoromisonidazole Positron Emission Tomography Imaging in Neck Nodal Metastases. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1403-1410.	0.4	102
163	Non-invasive imaging of angiogenesis in head and neck squamous cell carcinoma. Angiogenesis, 2010, 13, 149-160.	3.7	31
164	Multicopper oxidases: an innovative approach for oxygen management of aerobic organisms. Rendiconti Lincei, 2010, 21, 71-80.	1.0	2
165	Newer imaging techniques in head and neck cancer. Indian Journal of Surgical Oncology, 2010, 1, 186-193.	0.3	4
166	Measurement of reoxygenation during fractionated radiotherapy in head and neck squamous cell carcinoma xenografts. Australasian Physical and Engineering Sciences in Medicine, 2010, 33, 251-263.	1.4	9
167	Cancer stem cells at the crossroads of current cancer therapy failuresâ€"Radiation oncology perspective. Seminars in Cancer Biology, 2010, 20, 116-124.	4.3	97

#	Article	IF	CITATIONS
168	HIF- $1\hat{1}\pm$ inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer, 2010, 10, 605.	1.1	85
169	Hypoxia-specific targets in cancer therapy: role of splice variants. BMC Medicine, 2010, 8, 45.	2.3	12
170	The role of HIF prolyl hydroxylases in tumour growth. Journal of Cellular and Molecular Medicine, 2010, 14, 758-770.	1.6	83
171	hsaâ€miRâ€210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 2010, 116, 2148-2158.	2.0	215
172	Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [18F]-FAZA. Bioorganic and Medicinal Chemistry, 2010, 18, 2255-2264.	1.4	9
173	Radiation Resistance of Cancer Stem Cells: The 4 R's of Radiobiology Revisited. Stem Cells, 2010, 28, 639-648.	1.4	328
174	Induction of invasion in an organotypic oral cancer model by CoCl ₂ , a hypoxia mimetic. European Journal of Oral Sciences, 2010, 118, 168-176.	0.7	18
175	Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. British Journal of Cancer, 2010, 102, 428-435.	2.9	440
176	Therapeutic Ratio of Reirradiation with Cytotoxic Drugs and Other Response-Modifying Agents. Medical Radiology, 2010, , 37-57.	0.0	0
177	Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics. Clinical Cancer Research, 2010, 16, 4843-4852.	3.2	81
178	Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. Journal of Clinical Oncology, 2010, 28, 2989-2995.	0.8	339
179	Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. Journal of Nuclear Medicine, 2010, 51, 37-45.	2.8	68
180	Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer. Molecular Cancer Therapeutics, 2010, 9, 1755-1763.	1.9	43
181	Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment. Cancer Research, 2010, 70, 8045-8054.	0.4	211
182	"Contextual―Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair. Clinical Cancer Research, 2010, 16, 4553-4560.	3.2	100
183	Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments. Current Medicinal Chemistry, 2010, 17, 3045-3057.	1.2	80
184	Near Infrared Luminescent Oxygen Nanosensors with Nanoparticle Matrix Tailored Sensitivity. Analytical Chemistry, 2010, 82, 8446-8455.	3.2	91
185	Side population and cancer stem cells: Therapeutic implications. Cancer Letters, 2010, 288, 1-9.	3.2	109

#	Article	IF	CITATIONS
186	Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma. Journal of Clinical Oncology, 2010, 28, 4912-4918.	0.8	264
187	HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiotherapy and Oncology, 2010, 94, 30-35.	0.3	177
188	Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiotherapy and Oncology, 2010, 95, 3-22.	0.3	225
189	Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiotherapy and Oncology, 2010, 97, 176-182.	0.3	65
190	The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiotherapy and Oncology, 2010, 95, 371-380.	0.3	144
191	PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncology, The, 2010, 11, 661-669.	5.1	105
192	Evaluating repetitive $<$ sup $>$ 18 $<$ /sup $>$ F-fluoroazomycin-arabinoside ($<$ sup $>$ 18 $<$ /sup $>$ FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncoló gica, 2010, 49, 941-947.	0.8	68
193	Dose- and LET-painting with particle therapy. Acta Oncológica, 2010, 49, 1170-1176.	0.8	120
194	Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol \hat{A}^3 gica, 2010, 49, 922-933.	0.8	35
195	Identifying hypoxia in human tumors: A correlation study between ¹⁸ F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncológica, 2010, 49, 934-940.	0.8	74
196	Feasibility of dose painting using volumetric modulated arc optimization and delivery. Acta Oncol \tilde{A}^3 gica, 2010, 49, 964-971.	0.8	42
197	Gene expression and hypoxia in breast cancer. Genome Medicine, 2011, 3, 55.	3.6	73
198	Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? $\hat{a} \in \text{``Results from the randomized DAHANCA 5 and 7 trials. Acta Oncológica, 2011, 50, 1006-1014.}$	0.8	49
199	Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers. Cancers, 2011, 3, 1232-1252.	1.7	52
200	Hematopoietic Growth Factors in Oncology. Cancer Treatment and Research, 2011, , .	0.2	5
201	Cancer Stem Cells in Solid Tumors. , 2011, , .		7
202	Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treatment Reviews, 2011, 37, 476-86.	3.4	29
203	Interventions that induce modifications in the tumor microenvironment. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2011, 15, 376-382.	0.6	10

#	Article	IF	Citations
205	Mechanisms of Radioresistance in Cancer Stem Cells. , 2011, , 345-360.		0
207	Intérêt des traceurs de l'hypoxie en radiothérapie. Medecine Nucleaire, 2011, 35, 621-624.	0.2	0
208	Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nuclear Medicine and Biology, 2011, 38, 771-780.	0.3	49
209	Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 411-420.	0.8	39
210	The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy $\hat{a} \in \text{``Results from the randomized DAHANCA 5 study. Radiotherapy and Oncology, 2011, 98, 28-33.}$	0.3	56
211	Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis. Radiotherapy and Oncology, 2011, 100, 22-32.	0.3	404
212	Changes in the fraction of total hypoxia and hypoxia subtypes in human squamous cell carcinomas upon fractionated irradiation: Evaluation using pattern recognition in microcirculatory supply units. Radiotherapy and Oncology, 2011, 101, 209-216.	0.3	17
213	Deregulation of cap-dependent mRNA translation increases tumour radiosensitivity through reduction of the hypoxic fraction. Radiotherapy and Oncology, 2011, 99, 385-391.	0.3	21
214	Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiotherapy and Oncology, 2011, 101, 190-197.	0.3	36
215	Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: A preclinical study. Radiotherapy and Oncology, 2011, 99, 418-423.	0.3	40
216	Assessment of tumor hypoxia and interstitial fluid pressure by gadomelitol-based dynamic contrast-enhanced magnetic resonance imaging. Radiotherapy and Oncology, 2011, 101, 217-222.	0.3	10
217	Perfusion Estimated With Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely With Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1176-1183.	0.4	63
218	Positron Emission Tomography in Head and Neck Cancer. Medical Radiology, 2011, , 363-385.	0.0	1
219	Solving the Puzzle of Metastasis: The Evolution of Cell Migration in Neoplasms. PLoS ONE, 2011, 6, e17933.	1.1	51
220	Strategies to improve radiotherapy with targeted drugs. Nature Reviews Cancer, 2011, 11, 239-253.	12.8	889
221	Targeting hypoxia in cancer therapy. Nature Reviews Cancer, 2011, 11, 393-410.	12.8	2,607
222	Mitochondrial DNA mutations in head and neck cancer are infrequent and lack prognostic utility. British Journal of Cancer, 2011, 104, 1319-1324.	2.9	26
223	Molecular Imaging–Based Dose Painting: A Novel Paradigm for Radiation Therapy Prescription. Seminars in Radiation Oncology, 2011, 21, 101-110.	1.0	252

#	Article	IF	Citations
224	The potential role of non-FDG-PET in the management of head and neck cancer. Oral Oncology, 2011, 47, 2-7.	0.8	12
225	Positron Emission Tomography Imaging of Cancer Biology: Current Status and Future Prospects. Seminars in Oncology, 2011, 38, 70-86.	0.8	98
226	Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Experimental and Molecular Pathology, 2011, 90, 215-225.	0.9	38
227	Volumetric modulated arc therapy: a review of current literature and clinical use in practice. British Journal of Radiology, 2011, 84, 967-996.	1.0	503
228	Reduction of [18F]Fluoromisonidazole Uptake After Neoadjuvant Chemotherapy for Head and Neck Squamous Cell Carcinoma. Molecular Imaging and Biology, 2011, 13, 227-231.	1.3	26
229	Tumor Hypoxia Imaging. Molecular Imaging and Biology, 2011, 13, 399-410.	1.3	99
230	Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF- $1\hat{l}_{\pm}$, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer, 2011, 11, 167.	1.1	171
231	In vivo Identification and Specificity assessment of mRNA markers of hypoxia in human and mouse tumors. BMC Cancer, 2011, 11, 63.	1.1	12
232	In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs. Radiation Oncology, 2011, 6, 116.	1.2	35
233	Local response to chemoradiation in T4 larynx cancer with cartilage invasion. Laryngoscope, 2011, 121, 106-110.	1.1	29
234	Imaging tumor hypoxia by magnetic resonance methods. NMR in Biomedicine, 2011, 24, 1-16.	1.6	86
235	Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome. Head and Neck, 2011, 33, 1387-1393.	0.9	28
236	Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of Hypoxia. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1188-1195.	0.4	148
237	Influence of Tumor Hypoxia on Stereotactic Ablative Radiotherapy (SABR): Response to Drs. Meyer and Timmerman. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1600.	0.4	3
238	Stereotactic Ablative Radiotherapy in the Framework of Classical Radiobiology: Response to Drs. Brown, Diehn, and Loo. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1599-1600.	0.4	4
239	High Stromal Carbonic Anhydrase IX Expression Is Associated With Decreased Survival in p16-Negative Head-and-Neck Tumors. International Journal of Radiation Oncology Biology Physics, 2011, 80, 249-257.	0.4	37
240	Nitroxides as Cancer Imaging Agents. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 347-358.	0.9	30
241	Metastatic Renal Cell Carcinoma: Relationship Between Initial Metastasis Hypoxia, Change After 1 Month's Sunitinib, and Therapeutic Response: An ¹⁸ F-Fluoromisonidazole PET/CT Study. Journal of Nuclear Medicine, 2011, 52, 1048-1055.	2.8	82

#	Article	IF	Citations
242	Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps. Physics in Medicine and Biology, 2011, 56, 2045-2057.	1.6	54
243	Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors. Current Medicinal Chemistry, 2011, 18, 2885-2892.	1.2	11
244	Development of a Hypoxia Gene Expression Classifier with Predictive Impact for Hypoxic Modification of Radiotherapy in Head and Neck Cancer. Cancer Research, 2011, 71, 5923-5931.	0.4	226
245	Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer. British Journal of Radiology, 2011, 84, 903-918.	1.0	24
246	Elusive Goal of Targeting Tumor Hypoxia for Therapeutic Gain. Journal of Clinical Oncology, 2012, 30, 1741-1743.	0.8	16
247	Hypoxia Imaging for Radiation Therapy Planning. Medical Radiology, 2012, , 891-900.	0.0	0
248	Lifetime-based photoacoustic oxygen sensing in vivo. Journal of Biomedical Optics, 2012, 17, 057004.	1.4	37
249	Modelling and simulation of the influence of acute and chronic hypoxia on [¹⁸ F]fluoromisonidazole PET imaging. Physics in Medicine and Biology, 2012, 57, 1675-1684.	1.6	30
250	An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in	1.6	59
251	Time-gated Cherenkov emission spectroscopy from linear accelerator irradiation of tissue phantoms. Optics Letters, 2012, 37, 1193.	1.7	74
252	Quantitative Cherenkov emission spectroscopy for tissue oxygenation assessment. Optics Express, 2012, 20, 5133.	1.7	36
253	Single-fraction simulation of relative cell survival in response to uniform versus hypoxia-targeted dose escalation. Physics in Medicine and Biology, 2012, 57, 2757-2774.	1.6	3
254	Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial. Clinical Cancer Research, 2012, 18, 301-307.	3.2	47
255	Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer. Journal of Clinical Oncology, 2012, 30, 2102-2111.	0.8	447
256	<i>In Vitro</i> and <i>In Vivo</i> Evaluation of [¹⁸ F]F-GAZ, a Novel Oxygen-Mimetic Azomycin-Glucose Conjugate, for Imaging Hypoxic Tumor. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 473-480.	0.7	6
257	Assessment of Response to Therapy. Medical Radiology, 2012, , 279-322.	0.0	2
258	Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells. Endocrine-Related Cancer, 2012, 19, 625-644.	1.6	37
259	The HYP-RT Hypoxic Tumour Radiotherapy Algorithm and Accelerated Repopulation Dose per Fraction Study. Computational and Mathematical Methods in Medicine, 2012, 2012, 1-13.	0.7	11

#	Article	IF	CITATIONS
260	<i>In Silico</i> Modelling of Treatment-Induced Tumour Cell Kill: Developments and Advances. Computational and Mathematical Methods in Medicine, 2012, 2012, 1-16.	0.7	20
261	Targeted nanosensor aided three-dimensional pH mapping in tumor spheroids using two-photon microscopy. , 2012, , .		3
262	Imaging of Hypoxia Using PET and MRI. Current Pharmaceutical Biotechnology, 2012, 13, 552-570.	0.9	34
263	Different Distribution of 62Cu ATSM and 18F-FDG in Head and Neck Cancers. Clinical Nuclear Medicine, 2012, 37, 252-257.	0.7	19
264	The relationship between tissue oxygenation and redox status using magnetic resonance imaging. International Journal of Oncology, 2012, 41, 2103-2108.	1.4	17
265	Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy. Clinical Cancer Research, 2012, 18, 5585-5594.	3.2	374
266	Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity. Strahlentherapie Und Onkologie, 2012, 188, 865-872.	1.0	5
267	Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiotherapy and Oncology, 2012, 102, 122-129.	0.3	196
268	Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: A comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. Radiotherapy and Oncology, 2012, 105, 29-35.	0.3	66
269	Vascular abnormalities associated with acute hypoxia in human melanoma xenografts. Radiotherapy and Oncology, 2012, 105, 72-78.	0.3	8
270	Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: An exploratory study. Radiotherapy and Oncology, 2012, 105, 41-48.	0.3	18
271	Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo. Radiotherapy and Oncology, 2012, 105, 57-63.	0.3	20
272	Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiotherapy and Oncology, 2012, 105, 36-40.	0.3	37
273	New Tracers PET in Head and Neck Squamous Cell Carcinoma. PET Clinics, 2012, 7, 431-441.	1.5	2
274	Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol \tilde{A}^3 gica, 2012, 51, 419-432.	0.8	71
275	Head and Neck Cancer Imaging. Medical Radiology, 2012, , .	0.0	17
276	Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma – A prospective study. Radiotherapy and Oncology, 2012, 103, 38-44.	0.3	103
277	TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer, 2012, 12, 391.	1.1	80

#	Article	IF	CITATIONS
278	Hypoxia Imaging Markers and Applications for Radiation Treatment Planning. Seminars in Nuclear Medicine, 2012, 42, 343-352.	2.5	32
279	Oropharynx Cancer. Current Problems in Cancer, 2012, 36, 334-415.	1.0	5
280	On the structural modification of 2-nitroimidazole-99mTc(CO)3 complex, a hypoxia marker, for improving in vivo pharmacokinetics. Nuclear Medicine and Biology, 2012, 39, 1236-1242.	0.3	26
281	FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiotherapy and Oncology, 2012, 105, 14-20.	0.3	266
282	Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors. Radiation Oncology, 2012, 7, 78.	1.2	20
283	Definitive Radiotherapy versus Postoperative Radiotherapy of Patients with Oro- and Hypopharyngeal Cancer: Impact of Prognostic Factors. Journal of Oncology, 2012, 2012, 1-10.	0.6	2
284	Theranostic Oxygen Delivery Using Ultrasound and Microbubbles. Theranostics, 2012, 2, 1174-1184.	4.6	79
285	Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor. International Journal of Molecular Medicine, 2012, 29, 541-549.	1.8	9
286	Intra- and intertumor heterogeneities in total, chronic, and acute hypoxia in xenografted squamous cell carcinomas. Strahlentherapie Und Onkologie, 2012, 188, 606-615.	1.0	11
287	The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 272-296.	3.3	116
288	Hypoxia Gene Expression Signatures as Prognostic and Predictive Markers in Head and Neck Radiotherapy. Seminars in Radiation Oncology, 2012, 22, 119-127.	1.0	66
289	Introduction: Towards Predicting Outcome of Radiotherapyâ€"At Last. Seminars in Radiation Oncology, 2012, 22, 87-90.	1.0	2
290	The expression of HIF- $1\hat{l}_{\pm}$ in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Molecular Biology Reports, 2012, 39, 2021-2029.	1.0	43
291	Targeting tumor hypoxia in nasopharyngeal carcinoma. Head and Neck, 2013, 35, 133-145.	0.9	51
292	Molecular basis of  hypoxic' breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling. Radiation Oncology, 2013, 8, 46.	1.2	24
293	Pilot study of PET imaging of 1241-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer. EJNMMI Research, 2013, 3, 42.	1.1	12
294	The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia. Radiotherapy and Oncology, 2013, 108, 529-534.	0.3	44
295	Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiotherapy and Oncology, 2013, 108, 523-528.	0.3	80

#	Article	IF	CITATIONS
296	New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1 $\hat{1}$ ± signaling is essential for promoting adaptation and survival to hypoxia. Radiotherapy and Oncology, 2013, 108, 541-547.	0.3	41
297	Hypoxiaâ€inducible factors as key regulators of tumor inflammation. International Journal of Cancer, 2013, 132, 2721-2729.	2.3	60
298	Molecular and cellular processes underlying the hallmarks of head and neck cancer. European Archives of Oto-Rhino-Laryngology, 2013, 270, 2585-2593.	0.8	33
299	Old but new methods in radiation oncology: hyperbaric oxygen therapy. International Journal of Clinical Oncology, 2013, 18, 364-370.	1.0	29
300	Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: Correlation between primary and xenograft tumors. Head and Neck, 2013, 36, n/a-n/a.	0.9	9
301	Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol \tilde{A}^3 gica, 2013, 52, 1257-1271.	0.8	50
302	Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: Experimental and clinical evidence. Radiotherapy and Oncology, 2013, 106, 130-137.	0.3	28
303	Adenovirus-Mediated Transcriptional Targeting of Colorectal Cancer and Effects on Treatment-Resistant Hypoxic Cells. Clinical Colorectal Cancer, 2013, 12, 152-162.e1.	1.0	8
304	Contemporary Radiotherapy in Head and Neck Cancer. Surgical Oncology Clinics of North America, 2013, 22, 579-598.	0.6	14
305	Biological Consequences of Radiation-induced DNA Damage: Relevance to Radiotherapy. Clinical Oncology, 2013, 25, 578-585.	0.6	487
306	Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence. Journal of Biological Chemistry, 2013, 288, 37138-37153.	1.6	22
307	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clinical Cancer Research, 2013, 19, 4879-4888.	3.2	214
308	Potential of [18F]-Fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas. Strahlentherapie Und Onkologie, 2013, 189, 1015-1019.	1.0	18
309	Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiation Oncology, 2013, 8, 262.	1.2	16
310	Clinical perspectives of cancer stem cell research in radiation oncology. Radiotherapy and Oncology, 2013, 108, 388-396.	0.3	93
311	[18F]fluoromisonidazole and a New PET System With Semiconductor Detectors and a Depth of Interaction System for Intensity Modulated Radiation Therapy for Nasopharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 142-147.	0.4	19
312	Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: Potential role of hypoxia. Cancer Letters, 2013, 341, 63-72.	3.2	203
313	Synthesis and biological evaluation of a novel 99mTc labeled 2-nitroimidazole derivative as a potential agent for imaging tumor hypoxia. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3704-3708.	1.0	16

#	Article	IF	CITATIONS
314	Functional Imaging for Radiation Treatment Planning, Response Assessment, and Adaptive Therapy in Head and Neck Cancer. Radiographics, 2013, 33, 1909-1929.	1.4	73
315	Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiotherapy and Oncology, 2013, 108, 517-522.	0.3	42
316	Tumor Oxygen Measurements and Personalized Medicine. Advances in Experimental Medicine and Biology, 2013, 765, 195-201.	0.8	4
317	Positron emission tomography radiotracers for imaging hypoxia. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 244-250.	0.5	21
318	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Cancer and Metastasis Reviews, 2013, 32, 479-492.	2.7	46
319	Cancer metabolism, stemness and tumor recurrence. Cell Cycle, 2013, 12, 1371-1384.	1.3	195
321	Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. European Journal of Cancer, 2013, 49, 156-165.	1.3	36
322	Lack of Prognostic Effect of Carbonic Anhydrase-9, Hypoxia Inducible Factor-1α and Bcl-2 in 286 Patients with Early Squamous Cell Carcinoma of the Glottic Larynx Treated with Radiotherapy. Clinical Oncology, 2013, 25, 59-65.	0.6	20
323	Prognostic Impact of Cigarette Smoking on the Survival of Patients with Established Nasopharyngeal Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2285-2294.	1.1	28
324	The prognostic significance of hypoxia inducing factor $1-\hat{l}\pm$ in oropharyngeal cancer in relation to human papillomavirus status. Oral Oncology, 2013, 49, 354-359.	0.8	24
325	<i>In vivo</i> oxygen sensing using lifetime based photoacoustic measurements. Proceedings of SPIE, 2013, , .	0.8	1
326	The Rationale for Fractionation in Radiotherapy. Clinical Journal of Oncology Nursing, 2013, 17, 412-417.	0.3	18
327	Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images. Acta OncolA³gica, 2013, 52, 1308-1313.	0.8	15
328	Altered fractionation outcomes for hypoxic head and neck cancer using the <i>HYP-RT </i> Monte Carlo model. British Journal of Radiology, 2013, 86, 20120443.	1.0	8
329	Hypoxia-regulated gene expression and prognosis in loco-regional gastroesophageal cancer. Acta Oncol \tilde{A}^3 gica, 2013, 52, 1327-1335.	0.8	14
330	Hypoxia Imaging With 18F-Fluoroerythronitroimidazole Integrated PET/CT and Immunohistochemical Studies in Nonâ€"Small Cell Lung Cancer. Clinical Nuclear Medicine, 2013, 38, 591-596.	0.7	39
331	PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4622-4627.	3.3	193
332	Interobserver Agreement of Qualitative Analysis and Tumor Delineation of ⟨sup⟩18⟨ sup⟩F-Fluoromisonidazole and 3′-Deoxy-3′-⟨sup⟩18⟨ sup⟩F-Fluorothymidine PET Images in Lung Cancer. Journal of Nuclear Medicine, 2013, 54, 1543-1550.	2.8	44

#	Article	IF	Citations
333	Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. Clinical Cancer Research, 2013, 19, 6741-6750.	3.2	268
334	High Reproducibility of Tumor Hypoxia Evaluated by ¹⁸ F-Fluoromisonidazole PET for Head and Neck Cancer. Journal of Nuclear Medicine, 2013, 54, 201-207.	2.8	134
335	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. BioMed Research International, 2013, 2013, 1-8.	0.9	32
336	The Tumor Microenvironment and Strategies to Improve Drug Distribution. Frontiers in Oncology, 2013, 3, 154.	1.3	106
337	Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and longâ€term outcomes in patients with locally advanced rectal cancers. Colorectal Disease, 2013, 15, 1232-1237.	0.7	26
338	Osteopontin expression is an independent factor for poor survival in oral squamous cell carcinoma: a computerâ€assisted analysis on TMA sections. Journal of Oral Pathology and Medicine, 2013, 42, 620-626.	1.4	11
339	Lacking hypoxia-mediated downregulation of E-cadherin in cancers of the uterine cervix. British Journal of Cancer, 2013, 108, 402-408.	2.9	15
340	¹⁸ F-Fluoromisonidazole PET Uptake Is Correlated with Hypoxia-Inducible Factor-1α Expression in Oral Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2013, 54, 1060-1065.	2.8	49
341	Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. Nuclear Medicine Communications, 2013, 34, 155-161.	0.5	34
342	Tumor hypoxia as a driving force in genetic instability. Genome Integrity, 2013, 4, 5.	1.0	181
343	Quantifying Metabolic Heterogeneity in Head and Neck Tumors in Real Time: 2-DG Uptake Is Highest in Hypoxic Tumor Regions. PLoS ONE, 2014, 9, e102452.	1.1	25
344	Delivery-Corrected Imaging of Fluorescently-Labeled Glucose Reveals Distinct Metabolic Phenotypes in Murine Breast Cancer. PLoS ONE, 2014, 9, e115529.	1.1	23
345	Microwave-assisted Radiosynthesis of the Hypoxia Marker 1-α-D-(5-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf ([¹⁸ F]FAZA). Current Radiopharmaceuticals, 2014, 7, 49-56.	50 267 To 0.3	d (Deoxy-5-[a 2
346	Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer, 2014, 14, 858.	1.1	21
347	Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death and Disease, 2014, 5, e1018-e1018.	2.7	160
348	LET-painting increases tumour control probability in hypoxic tumours. Acta Oncológica, 2014, 53, 25-32.	0.8	112
349	Radiobiological modifiers in clinical radiation oncology: current reality and future potential. Future Oncology, 2014, 10, 2359-2379.	1.1	9
350	Imaging Tumor Hypoxia to Advance Radiation Oncology. Antioxidants and Redox Signaling, 2014, 21, 313-337.	2.5	77

#	Article	IF	CITATIONS
351	Assessment of the sensitivity and specificity of tissue-specific-based and anatomical-based optical biomarkers for rapid detection of human head and neck squamous cell carcinoma. Oral Oncology, 2014, 50, 848-856.	0.8	11
352	The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects. Cancers, 2014, 6, 1-27.	1.7	32
353	A voxelâ€based multiscale model to simulate the radiation response of hypoxic tumors. Medical Physics, 2015, 42, 90-102.	1.6	20
354	Current and emerging strategies to increase the efficacy of ionizing radiation in the treatment of cancer. Expert Opinion on Drug Discovery, 2014, 9, 167-181.	2.5	4
355	Multifunctional Nanoparticles in Radiation Oncology: An Emerging Paradigm. ACS Symposium Series, 2014, , 75-106.	0.5	1
356	The Clinical Importance of Assessing Tumor Hypoxia: Relationship of Tumor Hypoxia to Prognosis and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2014, 21, 1516-1554.	2.5	323
357	Identification of Hypoxic Cells Using an Organotellurium Tag Compatible with Mass Cytometry. Angewandte Chemie - International Edition, 2014, 53, 11473-11477.	7. 2	37
358	Correlation of <scp>p</scp> 16 status, hypoxic imaging using [18 <scp>F</scp>]â€misonidazole positron emission tomography and outcome in patients with locoâ€regionally advanced head and neck cancer. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 89-97.	0.9	35
359	Preclinical safety and activity of recombinant VSV $\hat{a}\in \mathbb{R}$ FN $\hat{a}\in \hat{l}^2$ in an immunocompetent model of squamous cell carcinoma of the head and neck. Head and Neck, 2014, 36, 1619-1627.	0.9	14
361	EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle, 2014, 13, 42-51.	1.3	97
362	Potential role of hypoxia imaging using 18F-FAZA PET to guide hypoxia-driven interventions (carbogen) Tj ETQq0	0 8.ggBT /	Overlock 10 ⁻
363	Quantitative oxygenation venography from MRI phase. Magnetic Resonance in Medicine, 2014, 72, 149-159.	1.9	143
364	Genetic Susceptibility and Predictive Assays. , 2014, , 143-156.		1
365	Prodrug Strategies for Targeting Tumour Hypoxia. Cancer Drug Discovery and Development, 2014, , 283-328.	0.2	2
366	Clinical Imaging of Hypoxia. Cancer Drug Discovery and Development, 2014, , 179-201.	0.2	0
367	Evaluation of repeated [18F]EF5 PET/CT scans and tumor growth rate in experimental head and neck carcinomas. EJNMMI Research, 2014, 4, 65.	1.1	4
368	Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncológica, 2014, 53, 654-661.	0.8	32
369	Hypoxia in Head and Neck Cancer in Theory and Practice: A PET-Based Imaging Approach. Computational and Mathematical Methods in Medicine, 2014, 2014, 1-13.	0.7	11

#	Article	IF	CITATIONS
370	Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation. Frontiers in Oncology, 2014, 4, 1.	1.3	200
371	Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer. Clinical Cancer Research, 2014, 20, 1345-1354.	3.2	43
372	<i>In Vivo</i> Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. Clinical Cancer Research, 2014, 20, 6389-6397.	3.2	81
373	Hypoxia Provokes Base Excision Repair Changes and a Repair-Deficient, Mutator Phenotype in Colorectal Cancer Cells. Molecular Cancer Research, 2014, 12, 1407-1415.	1.5	47
374	The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma. Oral Oncology, 2014, 50, 200-207.	0.8	23
375	A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1544-1552.	3.3	97
376	DW-MRI in assessment of the hypoxic fraction, interstitial fluid pressure, and metastatic propensity of melanoma xenografts. BMC Cancer, 2014, 14, 92.	1.1	30
377	Hypoxia and Cancer. Cancer Drug Discovery and Development, 2014, , .	0.2	7
378	Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. Radiotherapy and Oncology, 2014, 110, 342-347.	0.3	72
379	A study on nitroimidazole-99mTc(CO)3 complexes as hypoxia marker: Some observations towards possible improvement in in vivo efficacy. Nuclear Medicine and Biology, 2014, 41, 600-610.	0.3	26
380	Gene expression changes during repopulation in a head and neck cancer xenograft. Radiotherapy and Oncology, 2014, 113, 139-145.	0.3	4
381	In vitro photoacoustic measurement of hemoglobin oxygen saturation using a single pulsed broadband supercontinuum laser source. Applied Optics, 2014, 53, 3884.	0.9	59
382	Altered Fractionation Schedules in Radiation Treatment: A Review. Seminars in Oncology, 2014, 41, 730-750.	0.8	30
383	PET/CT imaging in cancer: Current applications and future directions. Cancer, 2014, 120, 3433-3445.	2.0	170
384	Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa. Radiotherapy and Oncology, 2014, 112, 23-29.	0.3	5
386	Tumor Hypoxia. , 2014, , 205-222.		0
387	Oxygen distribution in tumors: A qualitative analysis and modeling study providing a novel Monte Carlo approach. Medical Physics, 2014, 41, 094101.	1.6	3
389	A retrospective study: the prevalence and prognostic value of anemia in patients undergoing radiotherapy for esophageal squamous cell carcinoma. World Journal of Surgical Oncology, 2014, 12, 244.	0.8	19

#	Article	IF	CITATIONS
390	Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: Potential to guide treatment? A systematic review. Oral Oncology, 2014, 50, 963-970.	0.8	74
391	Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2031-2041.	3.3	29
392	Connective tissue of cervical carcinoma xenografts: Associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI. Acta Oncol \tilde{A}^3 gica, 2014, 53, 6-15.	0.8	19
393	Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. Radiation Oncology, 2014, 9, 88.	1.2	114
394	Galectin-1 links tumor hypoxia and radiotherapy. Glycobiology, 2014, 24, 921-925.	1.3	21
395	Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers. Bioorganic and Medicinal Chemistry, 2014, 22, 2123-2132.	1.4	18
396	The Meaning, Measurement and Modification of Hypoxia in the Laboratory and the Clinic. Clinical Oncology, 2014, 26, 277-288.	0.6	173
397	HypoxamiRs and Cancer: From Biology to Targeted Therapy. Antioxidants and Redox Signaling, 2014, 21, 1220-1238.	2.5	102
398	Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. Diagnostic and Interventional Imaging, 2014, 95, 689-703.	1.8	52
399	Molecular Imaging of Tumor Hypoxia with Positron Emission Tomography. Radiation Research, 2014, 181, 335-349.	0.7	41
400	Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells. Oncology Reports, 2014, 32, 723-729.	1.2	17
401	Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review. Journal of Laryngology and Otology, 2015, 129, 1046-1052.	0.4	6
402	Prognostic value of the proliferation marker Kiâ€67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial. Head and Neck, 2015, 37, 171-176.	0.9	18
403	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget, 2015, 6, 28716-28730.	0.8	14
404	Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice. Diagnostics, 2015, 5, 96-112.	1.3	1
405	Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia. Genes, 2015, 6, 935-956.	1.0	43
406	The Six Rs of Head and Neck Cancer Radiotherapy. , 0, , .		2
407	Micro Regional Heterogeneity of 64Cu-ATSM and 18F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis. PLoS ONE, 2015, 10, e0141379.	1.1	4

#	Article	IF	CITATIONS
408	Significant Prognostic Impact of Chemoradiotherapy-Induced Hemoglobin Decrease on Treatment Outcomes of Nasopharyngeal Carcinoma. Journal of Cancer, 2015, 6, 502-510.	1.2	10
409	Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies. , 2015, , .		6
410	Contemporary Assessment and Management of Head and Neck Cancer Surgical Margins. , 2015, , .		5
411	The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation. Molecular Cancer Therapeutics, 2015, 14, 1928-1938.	1.9	54
412	Management of Acute Radiation Side Effects. Pediatric Oncology, 2015, , 203-221.	0.5	1
413	Tumour Hypoxia and the Hypoxia-Inducible Transcription Factors: Key Players in Cancer Progression and Metastasis., 2015,, 65-98.		4
414	Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypoxia, Proliferation, and Perfusion. International Journal of Radiation Oncology Biology Physics, 2015, 91, 942-951.	0.4	44
415	Predictive value of 18F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: A preclinical study. Radiotherapy and Oncology, 2015, 114, 189-194.	0.3	22
416	The association of 18F-FDG PET and glucose metabolism biomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas. Radiotherapy and Oncology, 2015, 117, 118-124.	0.3	29
417	Involvement of c-Myc in the proliferation of MCF-7 human breast cancer cells induced by bHLH transcription factor DEC2. International Journal of Molecular Medicine, 2015, 35, 815-820.	1.8	22
418	Evaluation of Hypoxia With Copper-Labeled Diacetyl-bis(N-Methylthiosemicarbazone). Seminars in Nuclear Medicine, 2015, 45, 177-185.	2.5	34
419	Optimizing Hypoxia Detection and Treatment Strategies. Seminars in Nuclear Medicine, 2015, 45, 163-176.	2.5	40
420	Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 795-805.	1.5	82
421	PET imaging biomarkers in head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 613-622.	3.3	27
422	A ^{99m} Tc-Labeled Misonidazole Analogue: Step Toward a ^{99m} Tc-Alternative to [¹⁸ F]Fluromisonidazole for Detecting Tumor Hypoxia. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 79-86.	0.7	10
424	elF2 kinases mediate \hat{I}^2 -lapachone toxicity in yeast and human cancer cells. Cell Cycle, 2015, 14, 630-640.	1.3	5
425	Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Radiotherapy and Oncology, 2015, 114, 161-166.	0.3	30
426	The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy. Research in Microbiology, 2015, 166, 244-254.	1.0	33

#	ARTICLE	IF	Citations
427	Osteopontinâ€integrin α _v β ₃ axis is crucial for 5â€fluorouracil resistance in oral squamous cell carcinoma. FEBS Letters, 2015, 589, 231-239.	1.3	13
428	The Clinical Significance of Hypoxia in Human Cancers. Seminars in Nuclear Medicine, 2015, 45, 110-121.	2.5	166
429	HPV Infection and Anemia Status Stratify the Survival of Early T2 Laryngeal Squamous Cell Carcinoma. Journal of Voice, 2015, 29, 356-362.	0.6	16
430	The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. Radiotherapy and Oncology, 2015, 116, 346-351.	0.3	26
431	GABARAPL1 is required for increased EGFR membrane expression during hypoxia. Radiotherapy and Oncology, 2015, 116, 417-422.	0.3	28
432	Quantitative Oxygen Extraction Fraction from 7-Tesla MRI Phase: Reproducibility and Application in Multiple Sclerosis. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 131-139.	2.4	45
434	Functional Imaging Biomarkers: Potential to Guide an Individualised Approach to Radiotherapy. Clinical Oncology, 2015, 27, 588-600.	0.6	13
435	Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality. Cancer Drug Discovery and Development, 2015, , 345-361.	0.2	0
436	Modulation of the tumor vasculature and oxygenation to improve therapy., 2015, 153, 107-124.		104
437	Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature. Oral Oncology, 2015, 51, 848-856.	0.8	25
438	Molecular Imaging Biomarkers of Resistance to Radiation Therapy for Spontaneous Nasal Tumors in Canines. International Journal of Radiation Oncology Biology Physics, 2015, 91, 787-795.	0.4	19
439	Imaging Advances for Target Volume Definition in Radiotherapy. Current Radiology Reports, 2015, 3, 1.	0.4	1
440	A cell-based high-throughput screening assay for radiation susceptibility using automated cell counting. Radiation Oncology, 2015, 10, 55.	1.2	8
441	Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: A planning study. Acta Oncol \hat{A}^3 gica, 2015, 54, 1008-1016.	0.8	50
442	Hypoxia and Predicting Radiation Response. Seminars in Radiation Oncology, 2015, 25, 260-272.	1.0	73
443	Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand. Clinical Cancer Research, 2015, 21, 1995-2000.	3.2	43
444	Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model. Molecular Cancer Therapeutics, 2015, 14, 2901-2908.	1.9	17
445	Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. Acta Oncológica, 2015, 54, 1355-1363.	0.8	57

#	Article	IF	CITATIONS
446	Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia $\hat{a} \in \hat{a}$ a simulation study. Acta Oncol \tilde{A}^3 gica, 2015, 54, 1370-1377.	0.8	61
447	A turn-on fluorescent probe for tumor hypoxia imaging in living cells. Chemical Communications, 2015, 51, 14739-14741.	2.2	74
448	Cellular and Molecular Mechanisms Underlying Oxygen-Dependent Radiosensitivity. Radiation Research, 2015, 183, 487-496.	0.7	47
449	Gene Expression Signatures as Biomarkers of Tumour Hypoxia. Clinical Oncology, 2015, 27, 547-560.	0.6	95
450	Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer Research, 2015, 75, 4211-4223.	0.4	65
451	Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. Lung Cancer, 2015, 90, 55-60.	0.9	28
452	New ways to image and target tumour hypoxia and its molecular responses. Radiotherapy and Oncology, 2015, 116, 352-357.	0.3	49
453	The Effects of Pulsed Radiation Therapy on Tumor Oxygenation in 2 Murine Models of Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 820-828.	0.4	13
454	Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers. Strahlentherapie Und Onkologie, 2015, 191, 217-224.	1.0	36
455	Targeting Hypoxic Adaptations of Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities. , 2015, , 311-329.		0
456	Stress Response Pathways in Cancer. , 2015, , .		3
457	Emerging biomarkers in head and neck cancer in the era of genomics. Nature Reviews Clinical Oncology, 2015, 12, 11-26.	12.5	264
458	High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer. Bratislava Medical Journal, 2016, 116, 201-204.	0.4	7
459	Current relevance of hypoxia in head and neck cancer. Oncotarget, 2016, 7, 50781-50804.	0.8	73
460	Pathophysiological Basis for the Formation of the Tumor Microenvironment. Frontiers in Oncology, 2016, 6, 66.	1.3	152
461	Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Frontiers in Oncology, 2016, 6, 69.	1.3	129
462	Autophagy-Dependent Secretion: Contribution to Tumor Progression. Frontiers in Oncology, 2016, 6, 251.	1.3	40
463	MATE2 Expression Is Associated with Cancer Cell Response to Metformin. PLoS ONE, 2016, 11, e0165214.	1.1	25

#	Article	IF	CITATIONS
464	Applications of "Hot―and "Cold―Bis(thiosemicarbazonato) Metal Complexes in Multimodal Imaging. Chemical Record, 2016, 16, 1380-1397.	2.9	18
465	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology. 2016. 121. 364-373.	0.3	130
466	Correlation of FMISO simulations with pimonidazoleâ€stained tumor xenografts: A question of O ₂ consumption?. Medical Physics, 2016, 43, 4113-4121.	1.6	2
467	The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer. Oncology Letters, 2016, 12, 3449-3456.	0.8	12
468	Photoacoustic monitoring of tumor and normal tissue response to radiation. Scientific Reports, 2016, 6, 21237.	1.6	64
469	Simulating hypoxia-induced acidic environment in cancer cells facilitates mobilization and redox-cycling of genomic copper by daidzein leading to pro-oxidant cell death: implications for the sensitization of resistant hypoxic cancer cells to therapeutic challenges. BioMetals, 2016, 29, 299-310.	1.8	9
470	The impact of hypoxia and its modification of the outcome of radiotherapy. Journal of Radiation Research, 2016, 57, i90-i98.	0.8	229
471	Future treatment directions for HPV-associated head and neck cancer based on radiobiological rationale and current clinical evidence. Critical Reviews in Oncology/Hematology, 2016, 103, 27-36.	2.0	18
472	Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. Radiotherapy and Oncology, 2016, 120, 76-80.	0.3	55
473	Biological Features of Human Papillomavirus-related Head and Neck Cancers Contributing to Improved Response. Clinical Oncology, 2016, 28, 467-474.	0.6	29
474	Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. British Journal of Cancer, 2016, 114, 1071-1077.	2.9	155
475	Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, 164, 152-169.		507
476	Oxygen-Enhanced MRI Is a Major Advance in Tumor Hypoxia Imaging. Cancer Research, 2016, 76, 769-772.	0.4	48
477	A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma. British Journal of Cancer, 2016, 115, 1096-1104.	2.9	10
478	Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a027094.	2.9	119
479	Therapeutic Ratio of Reirradiation with Cytotoxic Drugs and Other Response-Modifying Agents. Medical Radiology, 2016, , 47-73.	0.0	0
480	Assessment of predictive molecular variables in feline oral squamous cell carcinoma treated with stereotactic radiation therapy. Veterinary and Comparative Oncology, 2016, 14, 39-57.	0.8	24
481	Vessel segmentation from quantitative susceptibility maps for local oxygenation venography. , 2016, , .		16

#	Article	IF	CITATIONS
482	Prognostic value of hypoxia-regulated gene expression in loco-regional gastroesophageal cancer. Acta Oncol \tilde{A}^3 gica, 2016, 55, 652-655.	0.8	2
484	Overcoming radioresistance in head and neck squamous cell carcinoma. Oral Oncology, 2016, 63, 44-51.	0.8	35
485	The Role of Cancer Stem Cells in Tumour Radioresponse. , 2016, , 43-74.		0
486	Personalized Medicine. Europeanization and Globalization, 2016, , .	0.1	5
487	A theoretical stochastic control framework for adapting radiotherapy to hypoxia. Physics in Medicine and Biology, 2016, 61, 7136-7161.	1.6	14
488	Molecular Radio-Oncology. Recent Results in Cancer Research, 2016, , .	1.8	1
489	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2016, , .	0.8	3
490	Hypoxia as a Biomarker and for Personalized Radiation Oncology. Recent Results in Cancer Research, 2016, 198, 123-142.	1.8	26
491	Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers. Advances in Experimental Medicine and Biology, 2016, 899, 269-290.	0.8	3
492	Targeting hypoxia to overcome radiation resistance in head & mp; neck cancers: real challenge or clinical fairytale?. Expert Review of Anticancer Therapy, 2016, 16, 751-758.	1.1	36
493	Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. Critical Reviews in Oncology/Hematology, 2016, 103, 86-98.	2.0	18
494	Clinical development of new drug–radiotherapy combinations. Nature Reviews Clinical Oncology, 2016, 13, 627-642.	12.5	230
495	Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2139-2146.	3.3	51
496	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus–Related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 9-17.	0.4	121
497	Pulsed Radiation Therapy With Concurrent Cisplatin Results in Superior Tumor Growth Delay in a Head and Neck Squamous Cell Carcinoma Murine Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, 161-169.	0.4	12
498	The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2147-2154.	3.3	27
499	Temporal changes in tumor oxygenation and perfusion upon normo- and hyperbaric inspiratory hyperoxia. Strahlentherapie Und Onkologie, 2016, 192, 174-181.	1.0	9
500	DWâ€MRI and ¹⁸ Fâ€FLT PET for early assessment of response to radiation therapy associated with hypoxiaâ€driven interventions. Preclinical studies using manipulation of oxygenation and/or dose escalation. Contrast Media and Molecular Imaging, 2016, 11, 115-121.	0.4	4

#	Article	IF	CITATIONS
501	Oxygen and Perfusion Kinetics in Response to Fractionated Radiation Therapy in FaDu Head and Neck Cancer Xenografts Are Related to Treatment Outcome. International Journal of Radiation Oncology Biology Physics, 2016, 96, 462-469.	0.4	25
502	Neutral 99mTc(CO)3 complexes of "clicked―nitroimidazoles for the detection of tumor hypoxia. Journal of Radioanalytical and Nuclear Chemistry, 2016, 307, 69-77.	0.7	8
503	The influence of smoking on radiation-induced bystander signal production in esophageal cancer patients. Environmental Research, 2016, 147, 565-571.	3.7	7
504	Synthesis and evaluation of 18 F-labeled 4-nitrobenzyl derivatives for imaging tumor hypoxia with positron emission tomography: Comparison of 2-[18 F]fluoroethyl carbonate and 2-[18 F]fluoroethyl carbamate. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 584-588.	1.0	3
505	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^') HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
506	Tumor hypoxia: a new PET imaging biomarker in clinical oncology. International Journal of Clinical Oncology, 2016, 21, 619-625.	1.0	31
507	Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 617-625.	3.3	26
508	64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2. Journal of Nuclear Medicine, 2016, 57, 437-443.	2.8	15
509	Radiation oncology in the era of precision medicine. Nature Reviews Cancer, 2016, 16, 234-249.	12.8	636
510	Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs. Nature Protocols, 2016, 11, 781-794.	5.5	59
511	PET-based quantification of statistical properties of hypoxic tumor subvolumes in head and neck cancer. Physica Medica, 2016, 32, 23-35.	0.4	20
512	Dose-Response Modifiers in Radiation Therapy. , 2016, , 51-62.e3.		3
513	Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Advanced Drug Delivery Reviews, 2017, 109, 63-73.	6.6	247
514	Oxygen imaging of living cells and tissues using luminescent molecular probes. Journal of Photochemistry and Photobiology C: Photochemistry Reviews, 2017, 30, 71-95.	5.6	98
515	Tumor Hypoxia and Radiotherapy. , 2017, , 1-48.		0
516	Pharmacokinetic Analysis of Dynamic ¹⁸ F-Fluoromisonidazole PET Data in Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 911-919.	2.8	22
517	Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & mp; neck tumours? The ESCALOX protocol. Radiation Oncology, 2017, 12, 45.	1.2	27
518	Evaluation of the R2* value in invasive ductal carcinoma with respect to hypoxic-related prognostic factors using iterative decomposition of water and fat with echo asymmetry and least-squares emission (IDEAL). European Radiology, 2017, 27, 4316-4323.	2.3	7

#	Article	IF	CITATIONS
519	Differential pattern of HIF- $\hat{\Pi}$ ± expression in HNSCC cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect. British Journal of Cancer, 2017, 116, 1340-1349.	2.9	44
520	CXCR4: A New Player in an Old Scene?. Orl, 2017, 79, 34-42.	0.6	4
521	Molecular mechanisms of hypoxia in cancer. Clinical and Translational Imaging, 2017, 5, 225-253.	1.1	119
522	A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume― Radiotherapy and Oncology, 2017, 124, 513-520.	0.3	22
523	Association between hypoxic volume and underlying hypoxia-induced gene expression in oropharyngeal squamous cell carcinoma. British Journal of Cancer, 2017, 116, 1057-1064.	2.9	20
524	Clinical PET imaging of tumour hypoxia in lung cancer. Clinical and Translational Imaging, 2017, 5, 427-445.	1.1	0
525	Impact of hypoxia in head and neck cancer radiotherapy. Clinical and Translational Imaging, 2017, 5, 497-505.	1.1	3
526	CT Texture Analysis Potentially Predicts Local Failure in Head and Neck Squamous Cell Carcinoma Treated with Chemoradiotherapy. American Journal of Neuroradiology, 2017, 38, 2334-2340.	1.2	70
527	Classifying the evolutionary and ecological features of neoplasms. Nature Reviews Cancer, 2017, 17, 605-619.	12.8	303
528	Simulation of head and neck cancer oxygenation and doubling time in a 4D cellular model with angiogenesis. Scientific Reports, 2017, 7, 11037.	1.6	9
529	Therapeutic options to overcome tumor hypoxia in radiation oncology. Clinical and Translational Imaging, 2017, 5, 455-464.	1.1	6
530	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. Acta Oncol \tilde{A}^3 gica, 2017, 56, 1571-1576.	0.8	23
531	18 F-Fluoromisonidazole positron emission tomography (FMISO-PET) may reflect hypoxia and cell proliferation activity in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 261-270.	0.2	12
532	Cell-line dependent effects of hypoxia prior to irradiation in squamous cell carcinoma lines. Clinical and Translational Radiation Oncology, 2017, 5, 12-19.	0.9	14
533	EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochemistry and Biophysics, 2017, 75, 299-309.	0.9	3
534	Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer. Free Radical Biology and Medicine, 2017, 113, 564-570.	1.3	10
535	Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1183-1196.	0.4	109
536	Predictive value of hypoxia in advanced head and neck cancer after treatment with hyperfractionated radio-chemotherapy and hypoxia modification. Clinical and Translational Oncology, 2017, 19, 419-424.	1.2	15

#	Article	IF	CITATIONS
537	Hypometabolism as the ultimate defence in stress response: how the comparative approach helps understanding of medically relevant questions. Acta Physiologica, 2017, 219, 409-440.	1.8	33
538	Increasing the Therapeutic Ratio of Radiotherapy. Cancer Drug Discovery and Development, 2017, , .	0.2	2
539	New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. European Journal of Medicinal Chemistry, 2017, 127, 691-702.	2.6	22
540	Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. British Journal of Cancer, 2017, 116, 28-35.	2.9	20
541	Hypoxia induces differential expression patterns of osteopontin and CD44 in colorectal carcinoma. Oncology Reports, 2018, 39, 442-448.	1.2	10
542	Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma. Radiation Oncology, 2017, 12, 120.	1.2	34
543	In silico modelling of radiation effects towards personalised treatment in radiotherapy. AIP Conference Proceedings, 2017, , .	0.3	0
544	A Novel Hypoxia Imaging Endoscopy System. , 2017, , .		0
545	Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice. Frontiers in Pharmacology, 2017, 8, 531.	1.6	16
546	Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical Settings. Frontiers in Oncology, 2017, 7, 10.	1.3	66
547	Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors. Radiation Oncology, 2017, 12, 148.	1.2	9
548	Biomarker driven treatment of head and neck squamous cell cancer. Cancers of the Head & Neck, 2017, 2, 6.	6.2	19
549	Discovery of the Hypoxia-Activated Prodrug SN30000., 2017,, 58-94.		4
550	Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget, 2017, 8, 62742-62758.	0.8	186
551	DAHANCA 10 – Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiotherapy and Oncology, 2018, 127, 12-19.	0.3	32
552	How Advances in Imaging Will Affect Precision Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 101, 292-298.	0.4	37
553	Modeling of FMISO [F 18] nanoparticle PET tracer in normal-cancerous tissue based on real clinical image. Microvascular Research, 2018, 118, 20-30.	1.1	12
554	Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions. Scientific Reports, 2018, 8, 2233.	1.6	15

#	Article	IF	Citations
555	EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition. Autophagy, 2018, 14, 283-295.	4.3	38
557	Oxygenation Imaging by Nuclear Magnetic Resonance Methods. Methods in Molecular Biology, 2018, 1718, 297-313.	0.4	4
558	A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma. Scientific Reports, 2018, 8, 1420.	1.6	36
559	Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features. Radiotherapy and Oncology, 2018, 127, 36-42.	0.3	55
560	Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides. Journal of Medicinal Chemistry, 2018, 61, 1241-1254.	2.9	52
561	Synthesis and evaluation of an ¹⁸ F″abeled trifluoroborate derivative of 2â€nitroimidazole for imaging tumor hypoxia with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 370-379.	0.5	6
562	MiRNA–mRNA crosstalk in laryngeal squamous cell carcinoma based on the TCGA database. European Archives of Oto-Rhino-Laryngology, 2018, 275, 751-759.	0.8	10
563	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clinical Cancer Research, 2018, 24, 1364-1374.	3.2	45
564	Raman Spectroscopic Signatures Reveal Distinct Biochemical and Temporal Changes in Irradiated Human Breast Adenocarcinoma Xenografts. Radiation Research, 2018, 189, 497.	0.7	19
565	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. Future Oncology, 2018, 14, 751-769.	1.1	7
566	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. International Journal of Radiation Oncology Biology Physics, 2018, 101, 274-284.	0.4	50
567	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. Seminars in Radiation Oncology, 2018, 28, 2-11.	1.0	23
568	Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. Oncogene, 2018, 37, 1107-1118.	2.6	71
569	Optimal timing of fluorine-18-fluoromisonidazole positron emission tomography/computed tomography for assessment of tumor hypoxia in patients with head and neck squamous cell carcinoma. Nuclear Medicine Communications, 2018, 39, 859-864.	0.5	7
570	Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. Journal of Gastrointestinal Oncology, 2018, 9, 1044-1053.	0.6	5
571	Transcutaneous carbon dioxide enhances the antitumor effect of radiotherapy on oral squamous cell carcinoma. Oncology Reports, 2018, 40, 434-442.	1.2	4
572	Therapeutic targeting of tumor hypoxia and necrosis with antibody \hat{l}_{\pm} -radioconjugates. Antibody Therapeutics, 2018, 1, 55-63.	1.2	15
573	Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck. Oncology Research and Treatment, 2018, 41, 736-743.	0.8	13

#	Article	IF	CITATIONS
574	Computational models and tools. Medical Physics, 2018, 45, e1073-e1085.	1.6	5
575	Biological PET-guided adaptive radiotherapy for dose escalation in head and neck cancer: a systematic review. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 349-368.	0.4	15
576	Ozone Therapy as Adjuvant for Cancer Treatment: Is Further Research Warranted?. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-11.	0.5	38
577	A potential solution for eliminating hypoxia as a cause for radioresistance. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10548-10550.	3.3	21
578	LPA4-Mediated Vascular Network Formation Increases the Efficacy of Anti–PD-1 Therapy against Brain Tumors. Cancer Research, 2018, 78, 6607-6620.	0.4	28
579	A Two-Component Assay for Hypoxia Incorporating Long-Term Nitroreduction and Short-Term DNA-Damage Allows Differentiation of the Three Hypoxia Sub-types. Radiation Research, 2018, 190, 72-87.	0.7	3
580	The Promise of Novel Biomarkers for Head and Neck Cancer from an Imaging Perspective. International Journal of Molecular Sciences, 2018, 19, 2511.	1.8	18
581	Severe hypoxia increases expression of ATM and DNA-PKcs and it increases their activities through Src and AMPK signaling pathways. Biochemical and Biophysical Research Communications, 2018, 505, 13-19.	1.0	15
582	Lymph Node With the Highest FDG Uptake Predicts Distant Metastasis-Free Survival in Patients With Locally Advanced Nasopharyngeal Carcinoma. Clinical Nuclear Medicine, 2018, 43, e220-e225.	0.7	8
583	The hypoxic tumor microenvironment in vivo selects tumor cells with increased survival against genotoxic stresses. Cancer Letters, 2018, 431, 142-149.	3.2	8
584	Why develop photoactivated chemotherapy?. Dalton Transactions, 2018, 47, 10330-10343.	1.6	203
585	Correlation of hypoxia status with radiosensitizing effects of sodium glycididazole: A preclinical study. Oncology Letters, 2018, 15, 6481-6488.	0.8	4
586	Implantable biosensors and their contribution to the future of precision medicine. Veterinary Journal, 2018, 239, 21-29.	0.6	101
587	"Smart―Nanoprobes for Visualization of Tumor Microenvironments. Advanced Healthcare Materials, 2018, 7, e1800391.	3.9	47
588	Clinical trials targeting hypoxia. British Journal of Radiology, 2019, 92, 20170966.	1.0	24
589	Galectins as Molecular Targets for Therapeutic Intervention. International Journal of Molecular Sciences, 2018, 19, 905.	1.8	83
590	Preparation and preliminary evaluation of a tris-metronidazole-99mTc(CO)3 complex for targeting tumor hypoxia. Journal of Radioanalytical and Nuclear Chemistry, 2018, 317, 1203-1210.	0.7	6
591	Oxygen Sensing, Hypoxia Tracing and in Vivo Imaging with Functional Metalloprobes for the Early Detection of Non-communicable Diseases. Frontiers in Chemistry, 2018, 6, 27.	1.8	34

#	Article	IF	CITATIONS
592	Analyses of regional radiosensitivity of white matter structures along tract axes using novel white matter segmentation and diffusion imaging biomarkers. Physics and Imaging in Radiation Oncology, 2018, 6, 39-46.	1.2	8
593	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. Radiation Oncology, 2018, 13, 83.	1.2	23
594	Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2018, 8, 271.	1.3	9
595	Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. PLoS ONE, 2018, 13, e0194841.	1.1	7
596	Approaches to combat hypoxia in cancer therapy and the potential for in silico models in their evaluation. Physica Medica, 2019, 64, 145-156.	0.4	15
597	Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models. Cells, 2019, 8, 717.	1.8	14
598	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. Cancers, 2019, 11, 1057.	1.7	25
599	Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms. Cancers, 2019, 11, 889.	1.7	17
600	Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research. Cancers, 2019, 11, 1499.	1.7	31
601	Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. Biochemical Pharmacology, 2019, 169, 113641.	2.0	19
602	Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. International Journal of Radiation Biology, 2019, 95, 1597-1612.	1.0	26
603	The Potential Role of Radiomics and Radiogenomics in Patient Stratification by Tumor Hypoxia Status. Journal of the American College of Radiology, 2019, 16, 1329-1337.	0.9	16
604	The role of hypofractionated radiotherapy in the management of head and neck cancer – a modelling approach. Journal of Theoretical Biology, 2019, 482, 109998.	0.8	4
605	Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?. Cancers, 2019, 11, 112.	1.7	111
606	Oral Mucosal Malignancies., 2019, , 1249-1436.		7
607	<p>Prognostic values of preoperative platelet-to-lymphocyte ratio, albumin and hemoglobin in patients with non-metastatic colon cancer</p> . Cancer Management and Research, 2019, Volume 11, 3265-3274.	0.9	19
608	Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients. Cancers, 2019, 11, 583.	1.7	28
609	A Role of PET Agents Beyond FDG in Gynecology. Seminars in Nuclear Medicine, 2019, 49, 501-511.	2.5	6

#	Article	IF	CITATIONS
610	Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations. Clinical Breast Cancer, 2019, 19, 383-391.	1.1	20
611	Naphthalimides in fluorescent imaging of tumor hypoxia – An up-to-date review. Bioorganic Chemistry, 2019, 88, 102979.	2.0	42
612	Prognostic impact of cigarette smoking on the survival of patients with established esophageal squamous cell carcinoma receiving radiotherapy: A retrospective study from southern China. Experimental and Therapeutic Medicine, 2019, 17, 3671-3681.	0.8	3
613	Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancers. Nuclear Medicine Communications, 2019, 40, 73-78.	0.5	11
614	Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy <i>in vitro</i> . Nanotechnology, 2019, 30, 264001.	1.3	14
615	Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment. Cancer Research, 2019, 79, 2054-2064.	0.4	53
617	ATF4, Hypoxia and Treatment Resistance in Cancer. Cancer Drug Discovery and Development, 2019, , 75-108.	0.2	1
618	Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs. Clinical Oncology, 2019, 31, 290-302.	0.6	22
619	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. Radiotherapy and Oncology, 2019, 135, 43-50.	0.3	25
620	Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer. PLoS ONE, 2019, 14, e0213111.	1.1	22
621	Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. Frontiers in Immunology, 2019, 10, 407.	2.2	44
622	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clinical Cancer Research, 2019, 25, 4211-4223.	3.2	85
623	Approaches to Targeting Cancer Stem Cells in Solid Tumors. Current Stem Cell Research and Therapy, 2019, 14, 421-427.	0.6	3
624	A meta-analysis of the impact of neutrophil-to-lymphocyte ratio on treatment outcomes after radiotherapy for solid tumors. Medicine (United States), 2019, 98, e15369.	0.4	20
625	A Near-Infrared Phosphorescent Nanoprobe Enables Quantitative, Longitudinal Imaging of Tumor Hypoxia Dynamics during Radiotherapy. Cancer Research, 2019, 79, 4787-4797.	0.4	20
626	Exercise as Adjunct Therapy in Cancer. Seminars in Radiation Oncology, 2019, 29, 16-24.	1.0	91
627	Organ Preservation Protocols in T4 Laryngeal Cancer: a Review of the Literature. Indian Journal of Surgical Oncology, 2019, 10, 149-155.	0.3	2
628	Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer and Metastasis Reviews, 2019, 38, 113-129.	2.7	120

#	Article	IF	Citations
629	An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect. Neoplasia, 2019, 21, 159-171.	2.3	22
630	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. Radiotherapy and Oncology, 2019, 130, 97-103.	0.3	14
631	PET/MRI in Breast Cancer. Journal of Magnetic Resonance Imaging, 2019, 49, 328-342.	1.9	31
632	Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. British Journal of Radiology, 2019, 92, 20180642.	1.0	111
633	Radiation Therapy Reduced Blood Levels of LDH, HIF-1 \hat{l} ±, and miR-210 in OSCC. Pathology and Oncology Research, 2020, 26, 433-442.	0.9	10
634	Tumor Microenvironment. , 2020, , 108-126.e7.		3
635	Basics of Radiation Therapy. , 2020, , 431-460.e3.		4
636	DAHANCA 33: functional image-guided dose-escalated radiotherapy to patients with hypoxic squamous cell carcinoma of the head and neck (NCT02976051). Acta OncolA³gica, 2020, 59, 208-211.	0.8	9
637	Practical Radiation Oncology. , 2020, , .		5
638	Textural features of hypoxia PET predict survival in head and neck cancer during chemoradiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1056-1064.	3.3	21
639	Lesional Uptake of the Hypoxia Imaging Agent [18F] FAZA on PET/CT Predicts Progression in Metastatic Differentiated Thyroid Cancer. Clinical Thyroidology, 2020, 32, 480-483.	0.0	0
640	Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma. Reports of Practical Oncology and Radiotherapy, 2020, 25, 768-774.	0.3	7
641	Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188416.	3.3	46
642	CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer. Cells, 2020, 9, 1651.	1.8	107
643	Head and neck squamous cell carcinoma. Nature Reviews Disease Primers, 2020, 6, 92.	18.1	1,649
644	The Importance of the Tumor Microenvironment and Hypoxia in Delivering a Precision Medicine Approach to Veterinary Oncology. Frontiers in Veterinary Science, 2020, 7, 598338.	0.9	9
645	Photoacoustic and Magnetic Resonance Imaging of Hybrid Manganese Dioxide-Coated Ultra-Small NaGdF4 Nanoparticles for Spatiotemporal Modulation of Hypoxia in Head and Neck Cancer. Cancers, 2020, 12, 3294.	1.7	15
646	Synergy of hypoxia relief and chromatin remodeling to overcome tumor radiation resistance. Biomaterials Science, 2020, 8, 4739-4749.	2.6	14

#	Article	IF	CITATIONS
647	Dual-Tracer Assessment of Dynamic Changes in Reoxygenation and Proliferation Decrease During Fractionated Radiotherapy in Murine Tumors. Frontiers in Oncology, 2020, 10, 1046.	1.3	0
648	Tumour Biology Characterisation by Imaging in Clinic. Medical Radiology, 2020, , 325-360.	0.0	0
649	Targeting Tumor Hypoxia. Cancer Drug Discovery and Development, 2020, , 265-299.	0.2	1
650	How best to interpret measures of levels of oxygen in tissues to make them effective clinical tools for care of patients with cancer and other oxygenâ€dependent pathologies. Physiological Reports, 2020, 8, e14541.	0.7	23
651	Tumors Responsive to Autophagy-Inhibition: Identification and Biomarkers. Cancers, 2020, 12, 2463.	1.7	4
652	Positron Emission Tomography in Head and Neck Cancer. Medical Radiology, 2020, , 467-494.	0.0	0
654	Inside the hypoxic tumour: reprogramming of the DDR and radioresistance. Cell Death Discovery, 2020, 6, 77.	2.0	56
655	The Impacts of Different Types of Radiation on the CRT and PDL1 Expression in Tumor Cells Under Normoxia and Hypoxia. Frontiers in Oncology, 2020, 10, 1610.	1.3	15
656	Retooling Cancer Nanotherapeutics' Entry into Tumors to Alleviate Tumoral Hypoxia. Small, 2020, 16, e2003000.	5.2	36
657	Incubation Method for Loading Lonidamine in Oxygen Microbubbles for Targeted Drug Delivery. , 2020,		0
658	A novel nutritional risk score and prognosis of oral cancer patients: A prospective study. Oral Diseases, 2022, 28, 108-115.	1.5	3
659	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. Cancers, 2020, 12, 3743.	1.7	19
660	[18F]-HX4 PET/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials. Clinical and Translational Radiation Oncology, 2020, 23, 9-15.	0.9	12
661	Host Factors Independently Associated With Prognosis in Patients With Oral Cavity Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 699.	1.2	28
662	Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions. Seminars in Nuclear Medicine, 2020, 50, 562-583.	2.5	40
663	Specific requirements for translation of biological research into clinical radiation oncology. Molecular Oncology, 2020, 14, 1569-1576.	2.1	6
664	Most Cited Articles in Head and Neck Oncology. Ear, Nose and Throat Journal, 2020, 100, 014556132093492.	0.4	2
665	A lineage-tracing tool to map the fate of hypoxic tumour cells. DMM Disease Models and Mechanisms, 2020, 13 , .	1.2	4

#	Article	IF	CITATIONS
666	[18F]-FDG-PET/CT and [18F]-FAZA-PET/CT Hypoxia Imaging of Metastatic Thyroid Cancer: Association with Short-Term Progression After Radioiodine Therapy. Molecular Imaging and Biology, 2020, 22, 1609-1620.	1.3	3
667	Roles for Ca2+ and K+ channels in cancer cells exposed to the hypoxic tumour microenvironment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118644.	1.9	16
668	Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion. Cancers, 2020, 12, 851.	1.7	9
669	To breathe or not to breathe? Hypoxia after pulsed-electric field treatment reduces the effectiveness of electrochemotherapy in vitro. Bioelectrochemistry, 2021, 137, 107636.	2.4	1
670	Spectroscopic investigation of radiation-induced reoxygenation in radiation-resistant tumors. Neoplasia, 2021, 23, 49-57.	2.3	7
671	Editorial for: " <scp>3D</scp> Oxygenâ€Enhanced <scp>MR</scp> Imaging at <scp>3T MR</scp> System: Comparison With Thinâ€Section <scp>CT</scp> of Quantitative Capability for Pulmonary Functional Loss Assessment and Clinical Stage Classification of <scp>COPD</scp> in Smokersâ€. Journal of Magnetic Resonance Imaging, 2021, 53, 1052-1053.	1.9	0
672	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Post-Radiotherapy Setting., 2021,, 59-81.		0
673	Effect of Hypoxia on Proliferation and the Expression of the Genes HIF- $1\hat{l}\pm$ and JMJD1A in Head and Neck Squamous Cell Carcinoma Cell Lines. Anticancer Research, 2021, 41, 113-122.	0.5	4
674	Evaluation of Optimal Post-Injection Timing of Hypoxic Imaging with 18F-Fluoromisonidazole-PET/CT. Molecular Imaging and Biology, 2021, 23, 597-603.	1.3	1
675	Imaging Hypoxia. , 2021, , 869-895.		0
676	Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study. BioMed Research International, 2021, 2021, 1-10.	0.9	0
677	The anti-tumoral effects of the oxygen carrier YQ23 in a triple-negative breast cancer syngeneic model. Translational Cancer Research, 2021, 10, 656-668.	0.4	0
678	Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2459-2469.	3.2	40
679	Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers, 2021, 13, 1209.	1.7	18
680	Using the R Package Spatstat to Assess Inhibitory Effects of Microregional Hypoxia on the Infiltration of Cancers of the Head and Neck Region by Cytotoxic T Lymphocytes. Cancers, 2021, 13, 1924.	1.7	5
681	Predictive modeling of hypoxic head and neck cancers during fractionated radiotherapy with gold nanoparticle radiosensitization. Medical Physics, 2021, 48, 3120-3133.	1.6	5
682	Hypoxia-sensing CAR TÂcells provide safety and efficacy in treating solid tumors. Cell Reports Medicine, 2021, 2, 100227.	3.3	65
683	Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers. World Journal of Gastrointestinal Oncology, 2021, 13, 312-331.	0.8	7

#	Article	IF	CITATIONS
684	20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, 42, 102915.	0.6	15
685	Lost in application: Measuring hypoxia for radiotherapy optimisation. European Journal of Cancer, 2021, 148, 260-276.	1.3	21
686	A Mesoscale Computational Model for Microvascular Oxygen Transfer. Annals of Biomedical Engineering, 2021, 49, 3356-3373.	1.3	14
687	Interfering with Tumor Hypoxia for Radiotherapy Optimization. Journal of Experimental and Clinical Cancer Research, 2021, 40, 197.	3.5	70
688	Switching on prodrugs using radiotherapy. Nature Chemistry, 2021, 13, 805-810.	6.6	91
689	Oxygenation Status of Malignant Tumors vs. Normal Tissues: Critical Evaluation and Updated Data Source Based on Direct Measurements with pO2 Microsensors. Applied Magnetic Resonance, 2021, 52, 1451-1479.	0.6	25
690	Therapeutic targeting of the hypoxic tumour microenvironment. Nature Reviews Clinical Oncology, 2021, 18, 751-772.	12.5	185
691	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 3453.	1.7	6
692	Engineering Tools for Regulating Hypoxia in Tumour Models. Journal of Cellular and Molecular Medicine, 2021, 25, 7581-7592.	1.6	9
693	Real-Time Analysis of Oxygen Gradient in Oocyte Respiration Using a High-Density Microelectrode Array. Biosensors, 2021, 11, 256.	2.3	2
694	Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy. Biomedicine and Pharmacotherapy, 2021, 139, 111607.	2.5	27
695	Review of Tissue Oxygenation Sensing During Radiotherapy Based Upon Cherenkov-Excited Luminescence Imaging. Applied Magnetic Resonance, 0 , 1 .	0.6	1
696	Plasma Metabolic Phenotypes of HPV-Associated versus Smoking-Associated Head and Neck Cancer and Patient Survival. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1858-1866.	1.1	3
697	Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET. Frontiers in Oncology, 2021, 11, 731503.	1.3	22
698	Therapeutic Modification of Hypoxia. Clinical Oncology, 2021, 33, e492-e509.	0.6	12
699	Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies. Seminars in Radiation Oncology, 2021, 31, 309-323.	1.0	0
700	Anti-tumor effect of local injectable hydrogel-loaded endostatin alone and in combination with radiotherapy for lung cancer. Drug Delivery, 2021, 28, 183-194.	2.5	13
701	Effect of anaemia on the response to preoperative chemoradiotherapy for rectal cancer. ANZ Journal of Surgery, 2021, 91, E286-E291.	0.3	2

#	Article	IF	CITATIONS
704	The Role of Mammalian Coronins in Development and Disease. Sub-Cellular Biochemistry, 2008, 48, 124-135.	1.0	30
705	Dose Painting and Theragnostic Imaging: Towards the Prescription, Planning and Delivery of Biologically Targeted Dose Distributions in External Beam Radiation Oncology. Cancer Treatment and Research, 2008, , 40-61.	0.2	11
706	Endogenous Hypoxia Markers: Case Not Proven!., 2008, 614, 127-136.		35
707	Prognostic Potential Of The Pretherapeutic Tumor Oxygenation Status. Advances in Experimental Medicine and Biology, 2009, 645, 241-246.	0.8	57
708	Hypoxia, Angiogenesis, and Oral Cancer Metastasis., 2009, , 299-321.		1
709	Randomized Controlled Trials of the Erythroid-Stimulating Agents in Cancer Patients. Cancer Treatment and Research, 2010, 157, 195-215.	0.2	1
710	Hypoxia-Directed Drug Strategies to Target the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2014, 772, 111-145.	0.8	19
711	Hypoxia and Radiation Therapy. Cancer Drug Discovery and Development, 2014, , 265-281.	0.2	1
712	Clinical and Statistical Considerations when Assessing Oxygen Levels in Tumors: Illustrative Results from Clinical EPR Oximetry Studies. Advances in Experimental Medicine and Biology, 2020, 1232, 155-168.	0.8	10
713	Relationship between hemoglobin levels and tumor oxygenation. , 2008, , 265-282.		2
714	Tumor hypoxia and therapeutic resistance. , 2008, , 283-305.		8
715	Incidence and impact of anemia in radiation oncology. , 2008, , 249-263.		3
716	Oral Mucosal Malignancies. , 2018, , 1-188.		4
717	Anti-angiogenics and Radiation Therapy. , 2017, , 1-10.		2
718	Quantitative Cell Kill of Radio- and Chemotherapy. Medical Radiology, 2009, , 169-190.	0.0	1
719	Tumor Biology's Impact on Clinical Cure Rates. Medical Radiology, 2009, , 323-334.	0.0	6
720	Pathophysiology of Solid Tumors. Medical Radiology, 2009, , 51-92.	0.0	43
721	Chemical Modifiers of Radiation Response. , 2010, , 55-68.		9

#	Article	IF	CITATIONS
722	Dose-Response Modifiers in Radiation Therapy. , 2012, , 53-64.		1
725	Radiotherapy-induced Cherenkov luminescence imaging in a human body phantom. Journal of Biomedical Optics, 2018, 23, 1.	1.4	7
726	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCl Insight, $2018, 3, .$	2.3	44
727	The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. Journal of Clinical Investigation, 2010, 120, 127-141.	3.9	675
728	Cherenkov emission spectroscopy for tissue oxygen saturation assessment. , 2012, , .		2
729	Quantitative diffuse reflectance spectroscopy of short-term changes in tumor oxygenation after radiation in a matched model of radiation resistance. Biomedical Optics Express, 2018, 9, 3794.	1.5	15
730	Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation. PLoS Biology, 2017, 15, e2002623.	2.6	41
731	Rapid Determination of Oxygen Saturation and Vascularity for Cancer Detection. PLoS ONE, 2013, 8, e82977.	1.1	14
732	Intermittent Hypoxia Effect on Osteoclastogenesis Stimulated by Neuroblastoma Cells. PLoS ONE, 2014, 9, e105555.	1.1	9
733	Non-Invasive, Simultaneous Quantification of Vascular Oxygenation and Glucose Uptake in Tissue. PLoS ONE, 2015, 10, e0117132.	1.1	24
734	The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin. Radiology and Oncology, 2016, 50, 113-120.	0.6	16
736	To predict the radiosensitivity of nasopharyngeal carcinoma using intravoxel incoherent motion MRI at 3.0 T. Oncotarget, 2017, 8, 53740-53750.	0.8	11
737	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. Oncotarget, 2017, 8, 108786-108801.	0.8	22
738	Targeting Notch to overcome radiation resistance. Oncotarget, 2016, 7, 7610-7628.	0.8	50
739	Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging. Chinese Clinical Oncology, 2016, 5, 24-24.	0.4	4
740	Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials. Current Angiogenesis, 2012, 1, 169-179.	0.1	19
741	Temporal variation in the response of tumors to hyperoxia with breathing carbogen and oxygen. Medical Gas Research, 2016, 6, 138.	1,2	4
742	Prognostic Significance of Glycolytic Metabolic Change Related to HIF-1α in Oral Squamous Cell Carcinomas. Korean Journal of Pathology, 2010, 44, 360.	1.2	2

#	Article	IF	CITATIONS
743	Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO — a selected review. Nuclear Medicine Review, 2011, 14, 90-95.	0.3	67
744	Prognostic Value of Osteopontin in Patients Treated with Primary Radiotherapy for Head and Neck Cancer. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5175-5178.	0.5	8
745	Physiological roles of mammalian transmembrane adenylyl cyclase isoforms. Physiological Reviews, 2022, 102, 815-857.	13.1	33
747	Treatment of anemia with rhEPO in radiation oncology. , 2008, , 615-634.		0
748	Prognostic and Predictive Markers in Radiation Therapy: Focus on Prostate Cancer. Cancer Treatment and Research, 2008, , 95-112.	0.2	0
749	One-stop-shop tumor imaging: buy hypoxia, get lactate free. Journal of Clinical Investigation, 2008, 118, 1616-9.	3.9	6
750	Assessment of Drug Resistance in Anticancer Therapy by Nuclear Imaging., 2009,, 295-313.		1
751	Significance of the Tumour Microenvironment in Radiotherapy. , 2009, , 137-156.		0
752	Dose-Escalated High-Precision Radiotherapy: a Method to Overcome Variations in Biology and Radiosensitivity Limiting the Success of Conventional Approaches?. Medical Radiology, 2009, , 335-346.	0.0	0
753	Tumor Imaging with Special Emphasis on the Role of Positron Emission Tomography in Radiation Treatment Planning. Medical Radiology, 2009, , 153-167.	0.0	0
754	Hypoxia in Head and Neck Cancers: Clinical Relevance and Treatment. , 2011, , 169-178.		0
755	Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2011, 29, 20.	0.1	1
756	De rol van radiotherapie bij de behandeling van kanker. , 2011, , 165-174.		0
757	Morphologic Investigations in Head and Neck Cancer. , 2011, , 201-219.		0
758	Time-gated Cherenkov emission spectroscopy from linear accelerator irradiation of tissue phantoms. , 2012, , .		4
759	Basics of Radiation Therapy. , 2014, , 393-422.e3.		1
760	Disorders of Blood Cell Production in Clinical Oncology. , 2014, , 532-541.e10.		2
761	Chronic Physiological Hypoxia and High Glucose Concentration Promote Resistance of T98G Glioblastoma Cell Line to Temozolomide. Drug Designing: Open Access, 2014, 03, .	0.2	1

#	Article	IF	Citations
762	Kopf-Hals-Tumoren. , 2016, , 631-672.		0
763	Imaging of Head and Neck Cancers. , 2016, , 243-264.		0
764	Hypoxia in Head and Neck Cancers: Clinical Relevance and Treatment. , 2016, , 229-242.		0
765	The Role of Radiology in Personalized Medicine. Europeanization and Globalization, 2016, , 219-230.	0.1	O
766	PET/CT in der Strahlentherapie. , 2016, , 689-724.		0
767	Application of Functional Molecular Imaging in Radiation Oncology. Cancer Drug Discovery and Development, 2017, , 103-134.	0.2	0
768	Hypoxia in Head and Neck Cancer., 2017,, 59-95.		0
769	Quantitative Diffuse Optical Spectroscopy of Short-term Reoxygenation Kinetics in Radiation-Resistant and Sensitive Tumors. , 2017, , .		0
770	De rol van radiotherapie bij de behandeling van kanker. , 2017, , 125-136.		0
771	Development of an oxygen saturation measuring system by using near-infrared spectroscopy. , 2017, , .		1
773	Multispectral Near-Infrared Optical Tomography for Cancer Hypoxia Study in Mice. Advances in Experimental Medicine and Biology, 2018, 1072, 165-169.	0.8	0
774	The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. Current Cancer Research, 2018, , 397-438.	0.2	0
775	A Volumetric Delta TCP Tool to Quantify Treatment Outcome Effectiveness Based on Biological Parameters and Different Dose Distributions. IFMBE Proceedings, 2019, , 677-681.	0.2	0
776	Anti-angiogenics and Radiation Therapy. , 2019, , 349-358.		0
777	6Rs of Radiation Oncology. , 2020, , 177-178.		0
778	Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer. Molecular Imaging and Biology, 2022, 24, 208-219.	1.3	4
779	Molecular Imaging in Photon Radiotherapy. Recent Results in Cancer Research, 2020, 216, 845-863.	1.8	1
780	T-Staging and Target Volume Definition by Imaging in Head and Neck Tumors. Medical Radiology, 2020, , 169-181.	0.0	0

#	Article	IF	CITATIONS
781	De rol van radiotherapie bij de behandeling van kanker. , 2020, , 133-147.		0
782	The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. International Journal of Radiation Biology, 2022, 98, 439-451.	1.0	24
783	Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy. Meditsinskiy Sovet, 2020, , 182-189.	0.1	0
785	Positron emission tomography for radiotherapy planning in head and neck cancer: What impact?. Nuclear Medicine Communications, 2021, 42, 234-243.	0.5	1
786	PET imaging of tumour hypoxia. Cancer Imaging, 2006, 6, 1-1.	1.2	15
788	Vascular development in mouse lung metastases. American Journal of Cancer Research, 2012, 2, 581-8.	1.4	2
789	Increase in gene-transcript levels as indicators of up-regulation of the unfolded protein response in spontaneous canine tumors. Canadian Journal of Veterinary Research, 2014, 78, 161-7.	0.2	0
791	Kinetic modeling in PET imaging of hypoxia. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 490-506.	1.0	17
792	Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic (18)F-FMISO-Pet-Ct and quantitative histology. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 348-62.	1.0	9
793	Hypoxia and Its Influence on Radiotherapy Response of HPV-Positive and HPV-Negative Head and Neck Cancer. Cancers, 2021, 13, 5959.	1.7	13
794	Secretion of proâ€angiogenic extracellular vesicles during hypoxia is dependent on the autophagyâ€related protein GABARAPL1. Journal of Extracellular Vesicles, 2021, 10, e12166.	5.5	14
795	Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, , .	0.4	4
796	Multiangle Long-Axis Lateral Illumination Photoacoustic Imaging to Evaluate Tumor Oxygenation. , 2021, , .		2
797	Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Drug Resistance Updates, 2022, 60, 100806.	6.5	41
798	AMPK increases expression of ATM through transcriptional factor Sp1 and induces radioresistance under severe hypoxia in glioblastoma cell lines. Biochemical and Biophysical Research Communications, 2022, 590, 82-88.	1.0	11
799	Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up. British Journal of Cancer, 2022, 126, 1145-1156.	2.9	20
800	Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling. Frontiers in Pharmacology, 2022, 13, 803602.	1.6	3
801	ATG12 deficiency results in intracellular glutamine depletion, abrogation of tumor hypoxia and a favorable prognosis in cancer. Autophagy, 2022, 18, 1898-1914.	4.3	11

#	Article	IF	CITATIONS
802	PET imaging of hypoxia and apoptosis. , 2022, , .		0
803	More than a Bubble: Extracellular Vesicle microRNAs in Head and Neck Squamous Cell Carcinoma. Cancers, 2022, 14, 1160.	1.7	13
804	Radiation and chemotherapy variable response induced by tumor cell hypoxia: impact of radiation dose, anticancer drug, and type of cancer. Radiation and Environmental Biophysics, 2022, 61, 263-277.	0.6	3
805	Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer. Clinical Cancer Research, 2022, 28, 1038-1052.	3.2	13
808	Exploring hypoxic biology to improve radiotherapy outcomes. Expert Reviews in Molecular Medicine, 2022, 24, e21.	1.6	4
809	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors. Cancers, 2022, 14, 2202.	1.7	3
810	Modeling the impact of spatial oxygen heterogeneity on radiolytic oxygen depletion during FLASH radiotherapy. Physics in Medicine and Biology, 2022, 67, 115017.	1.6	8
811	A predictive model for advanced oropharyngeal cancer patients treated with chemoradiation. BMC Cancer, 2022, 22, .	1.1	2
814	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical and Translational Immunology, 2022, 11 , .	1.7	10
815	The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia. Frontiers in Pharmacology, 0, 13, .	1.6	15
816	FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer. Journal of Personalized Medicine, 2022, 12, 1245.	1.1	7
817	Tumoral oxygenation and biodistribution of Lonidamine oxygen microbubbles following localized ultrasound-triggered delivery. International Journal of Pharmaceutics, 2022, 625, 122072.	2.6	4
818	Research progress on tumor hypoxia-associative nanomedicine. Journal of Controlled Release, 2022, 350, 829-840.	4.8	28
819	Biomarkers in Head and Neck Cancer. , 2022, , 129-151.		0
820	The measurement and modification of hypoxia in colorectal cancer: overlooked but not forgotten. Gastroenterology Report, 2022, 10, .	0.6	4
821	Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma. Cancers, 2022, 14, 4130.	1.7	6
822	Advances in Image-Guided Radiotherapy in the Treatment of Oral Cavity Cancer. Cancers, 2022, 14, 4630.	1.7	6
823	Value of Cytokine Expression in Early Diagnosis and Prognosis of Tumor Metastasis. Journal of Oncology, 2022, 2022, 1-9.	0.6	2

#	Article	IF	Citations
824	Bacteriolytic therapy with Clostridium ghonii for experimental solid tumors. Biochemical and Biophysical Research Communications, 2022, 634, 114-121.	1.0	2
825	ROS-Based Cancer Radiotherapy. Nanomedicine and Nanotoxicology, 2022, , 265-309.	0.1	1
826	Specific PET Tracers for Solid Tumors and for Definition of the Biological Target Volume., 2022,, 31-53.		0
827	Diffuse Reflectance Spectroscopy of Changes in Tumor Microenvironment in Response to Different Doses of Radiation. Radiation Research, 2022, 198, .	0.7	1
828	The emerging role of exosomes in radiotherapy. Cell Communication and Signaling, 2022, 20, .	2.7	9
829	How the histological structure of some lung cancers shaped almost 70 years of radiobiology. British Journal of Cancer, 2023, 128, 407-412.	2.9	3
830	Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer. Scientific Reports, 2022, 12, .	1.6	1
832	Nanoparticleâ€Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy. Advanced Materials, 2023, 35, .	11.1	29
833	Association between Tumor Microbiome and Hypoxia across Anatomic Subsites of Head and Neck Cancers. International Journal of Molecular Sciences, 2022, 23, 15531.	1.8	2
834	A systematic review verified by bioinformatic analysis based on TCGA reveals week prognosis power of CAIX in renal cancer. PLoS ONE, 2022, 17, e0278556.	1.1	1
835	Microbial Changes Associated With Oral Cavity Cancer Progression. Otolaryngology - Head and Neck Surgery, 0, , .	1.1	0
836	The effect of single bout and prolonged aerobic exercise on tumor hypoxia in mice. Journal of Applied Physiology, 2023, 134, 692-702.	1.2	3
837	Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma. Cancer Drug Resistance (Alhambra, Calif), 2023, 6, 116-137.	0.9	5
838	Application of radiomics in lung immunoâ€oncology. Precision Radiation Oncology, 2023, 7, 128-136.	0.4	1
839	Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer. Pharmaceutics, 2023, 15, 1207.	2.0	2
840	First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer. Radiotherapy and Oncology, 2023, 183, 109592.	0.3	16
841	Influence of 2-Nitroimidazoles in the Response of FaDu Cells to Ionizing Radiation and Hypoxia/Reoxygenation Stress. Antioxidants, 2023, 12, 389.	2.2	1
842	Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models. Molecular Pharmaceutics, 2023, 20, 2245-2255.	2.3	1

#	Article	IF	CITATIONS
843	Ozone in Chemotherapy-Induced Peripheral Neuropathyâ€"Current State of Art, Possibilities, and Perspectives. International Journal of Molecular Sciences, 2023, 24, 5279.	1.8	1
844	Improved Tumor Control Following Radiosensitization with Ultrasound-Sensitive Oxygen Microbubbles and Tumor Mitochondrial Respiration Inhibitors in a Preclinical Model of Head and Neck Cancer. Pharmaceutics, 2023, 15, 1302.	2.0	3
847	Radiosensitizer, Radiotherapie als Chemosensitizer. Springer Reference Medizin, 2022, , 1-7.	0.0	0
849	Classification and Evolution of Tumor Ecosystem. , 2023, , 655-674.		0
864	Kopf-Hals-Tumoren., 2024,, 517-554.		0
866	Strahlentherapie., 2024, , 579-594.		0
867	Praktischer Leitfaden fýr die klinische Anwendung. , 2024, , 89-108.		0